var title_f29_20_30016="Methylene blue stool answer";
var content_f29_20_30016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F62877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F62877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Methylene blue stain for fecal leukocytes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Methylene blue stain of stool (x1000) shows abundant polymorphonuclear leukocytes. Shigella flexneri grew from this specimen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30016=[""].join("\n");
var outline_f29_20_30016=null;
var title_f29_20_30017="Diverticulitis microperf CT";
var content_f29_20_30017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diverticulitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 315px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    68-year old man with acute diverticulitis of sigmoid colon. Axial CT scans obtained with colonic contrast material and 5 mm collimation show asymmetric inflammatory wall thickening (curved arrow) superimposed on muscular wall hypertrophy (black arrow), diverticula, fat stranding, and fascial thickening (thin white arrow). Note contained perforation with formation of phlegmon and extraluminal air (thick white arrow). No free intraperitoneal extravasation of colonic contrast material is seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From: Kircher MF, Rhea JT, Kihiczak D, Novelline RA. Frequency, Sensitivity, and Specificity of Individual Signs of Diverticulitis on Thin- Section Helical CT with Colonic Contrast Material. AJR Am J Roentgenol 2002; 178:1313. Reprinted with permission from the American Journal of Roentgenology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30017=[""].join("\n");
var outline_f29_20_30017=null;
var title_f29_20_30018="Erythematous leg lesion";
var content_f29_20_30018=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F78116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F78116&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythematous lesions of Kaposi sarcoma on the leg",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 287px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce J Dezube, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30018=[""].join("\n");
var outline_f29_20_30018=null;
var title_f29_20_30019="Sodium hypochlorite solution: Patient drug information";
var content_f29_20_30019=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium hypochlorite solution: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=see_link\">",
"     see \"Sodium hypochlorite solution: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Atrapro&trade; Dermal;",
"     </li>",
"     <li>",
"      Dakin's Solution;",
"     </li>",
"     <li>",
"      Di-Dak-Sol",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10017315\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691321",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to clean wounds.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to avoid or treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10017314\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702938",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to sodium hypochlorite solution or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10017319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10017320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10017322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10017317\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694771",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694520",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on affected part only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10017318\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10017323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10017324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12121 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-122.72.80.101-F770B2E4D0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30019=[""].join("\n");
var outline_f29_20_30019=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221802\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017315\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017314\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017319\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017320\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017322\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017317\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017318\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017323\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10017324\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?28/23/29042?source=related_link\">",
"      Sodium hypochlorite solution: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30020="Ofloxacin (ophthalmic): Patient drug information";
var content_f29_20_30020=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ofloxacin (ophthalmic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=see_link\">",
"     see \"Ofloxacin (ophthalmic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=see_link\">",
"     see \"Ofloxacin (ophthalmic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9496344\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ocuflox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9496345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Ocuflox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691501",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat eye infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702624",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ofloxacin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703760",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had tendons get irritated or torn when taking this drug or an alike drug in the past.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698045",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Eye irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698369",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tendons may rarely get irritated and tear.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698993",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain in back of the ankle.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698967",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain or swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For the eye only.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695783",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take out contact lenses before using this drug. Lenses may be put back in 15 minutes after this drug is given. Do not put contacts back in if your eyes are irritated or infected.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not touch the container tip to the eye, lid, or other skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696124",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tilt your head back and drop drug into the eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694401",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       After use, keep your eyes closed. Put pressure on the inside corner of the eye. Do this for 1 to 2 minutes. This keeps the drug in your eye.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Space each eye drug by 5 minutes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12270 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-3FB984B900-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30020=[""].join("\n");
var outline_f29_20_30020=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496344\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9496345\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024497\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024496\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024501\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024502\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024504\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024499\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024500\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024505\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024506\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/2/31780?source=related_link\">",
"      Ofloxacin (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/55/21363?source=related_link\">",
"      Ofloxacin (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?0/30/484?source=related_link\">",
"      Ofloxacin (otic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?16/6/16484?source=related_link\">",
"      Ofloxacin (otic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/42/20131?source=related_link\">",
"      Ofloxacin (otic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/41/1688?source=related_link\">",
"      Ofloxacin (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/29/30165?source=related_link\">",
"      Ofloxacin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/28/34246?source=related_link\">",
"      Ofloxacin (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30021="Prazosin: Pediatric drug information";
var content_f29_20_30021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prazosin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"    see \"Prazosin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37172?source=see_link\">",
"    see \"Prazosin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Minipress&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Prazo&reg;;",
"     </li>",
"     <li>",
"      Minipress&reg;;",
"     </li>",
"     <li>",
"      Novo-Prazin;",
"     </li>",
"     <li>",
"      Nu-Prazo;",
"     </li>",
"     <li>",
"      Teva-Prazosin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1055005\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Alpha-Adrenergic Blocking Agent, Oral",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Vasodilator",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1054997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=see_link\">",
"      see \"Prazosin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants, Children, and Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Children and Adolescents: Limited data available: Oral: Initial: 0.05-0.1 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses every 8 hours; may titrate up to 0.5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     in divided doses 3 times daily; maximum daily dose: 20 mg/",
"     <b>",
"      day",
"     </b>",
"     (NHBPEP, 2004; NHLBI, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Scorpion envenomation:",
"     </b>",
"     Limited data available:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Weight-directed: Infants &ge;4 months, Children, and Adolescents: Oral: 0.03 mg/kg/dose; second dose has been administered at 3 or 6 hours after initial dose; subsequent doses every 6 hours; therapy has been continued for 48 hours or until extremities are warm and dry (Bosnak, 2009; Gupta, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Fixed dosing: Infants &gt;6 months, Children, and Adolescents: Oral: 0.25 mg every 3 hours until extremities are warm and dry (Bawaskar, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Initial: 1 mg/dose 2-3 times/day; usual maintenance dose: 2-20 mg/day in divided doses 2-3 times/day (JNC 7); maximum daily dose: 20 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 1 mg, 2 mg, 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Minipress&reg;: 1 mg, 2 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1055009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer without regard to meals at the same time each day.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1055008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension alone or in combination with diuretics or beta-blockers (FDA approved in adults); has also been used in the management of the sympathetic stimulatory cardiovascular effects of scorpion envenomation  usually due to non-",
"     <i>",
"      Centruroides",
"     </i>",
"     species stings (typically found outside North America)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Prazosin may be confused with predniSONE",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212776\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema, orthostatic hypotension, palpitation, syncope",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Depression, dizziness, drowsiness, headache, nervousness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased energy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, reddened sclera",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, epistaxis, nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Abdominal discomfort, allergic reaction, alopecia, angina, arthralgia, bradycardia, cataplexy, cataracts (both development and disappearance have been reported), diaphoresis, enuresis, eye pain, fever, flushing, gynecomastia, hallucinations, impotence, insomnia, leukopenia, lichen planus, liver function abnormalities, malaise, MI, narcolepsy (worsened), pain, pancreatitis, paresthesia, pigmentary mottling and serous retinopathy, positive ANA titer, priapism, pruritus, systemic lupus erythematosus, tachycardia, tinnitus, urticaria, vasculitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reported in association with other alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers: Intraoperative floppy iris syndrome (with cataract surgery)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1055013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prazosin, quinazolines, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1054996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patient with cataracts or undergoing corrective cataract surgery; intraoperative floppy iris syndrome (IFIS) has been observed in cataract surgery patients who were on or were previously treated with alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers; there appears to be no benefit in discontinuing alpha",
"     <sub>",
"      1",
"     </sub>",
"     -blockers prior to surgery. Use with caution in patients with narcolepsy; worsening of symptoms has been reported although causality has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F15255518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Marked orthostatic hypotension, syncope, and loss of consciousness may occur with first dose, dose increase, or within first few days of therapy; syncope usually occurs 30-90 minutes post-initial dose; occasionally preceded with severe tachycardia (120-160 bpm in adults); anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, large initial dose (&gt;1 mg in adults), or if another antihypertensive drug (eg, beta-blockers, diuretics, and particularly vasodilators) or a PDE-5 inhibitor (eg, sildenafil, tadalafil, vardenafil) is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward. May cause priapism (rarely).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9838452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Induces",
"     </b>",
"     P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha-/Beta-Agonists. Similarly, Alpha-/Beta-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Agonists: Alpha1-Blockers may diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the antihypertensive effect of other Alpha1-Blockers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the orthostatic hypotensive effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Dabigatran Etexilate.  Management: Avoid concurrent use of dabigatran with p-glycoprotein inducers when possible.  Closely monitor for decreased levels/effects of dabigatran if concomitantly administering  p-glycoprotein inducers, particularly strong inducers.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Linagliptin: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Linagliptin.  Management: Strongly consider using an alternative to any strong P-glycoprotein inducer in patients who are being treated with linagliptin. If this combination is used, monitor patients closely for evidence of reduced linagliptin effectiveness.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on one agent prior to initiating the other, and always initiate combination using the lowest possible dose of the drug being added. When tadalafil is used for treatment of BPH, concurrent alpha 1-blockers are not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inducers may decrease the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1055015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid natural licorice (causes sodium and water retention and increases potassium loss); food has variable effects on absorption",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13459610\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. Limited use in pregnant women has not demonstrated any fetal abnormalities or adverse effects (Dommisse, 1983).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1055004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure (standing and sitting or supine)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1054995\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competitively inhibits postsynaptic alpha-adrenergic receptors which results in vasodilation of veins and arterioles and a decrease in total peripheral resistance and blood pressure",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1055011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antihypertensive: Within 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect: Antihypertensive: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 10-24 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1055012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.5 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein-binding: 92% to 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive in the liver, metabolites may be active",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 43% to 82%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: ~3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 2-3 hours, prolonged with CHF",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Feces; urine (6% to 10% renally as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1055002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37172?source=see_link\">",
"      see \"Prazosin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take consistently at same time each day. Avoid alcohol; rise slowly from sitting or lying position; may cause dizziness or drowsiness, headache, or nausea; ability to perform activities requiring mental alertness or physical coordination may be impaired; may cause dry mouth. Report increased nervousness or depression, sudden weight gain, palpitations or rapid heartbeat, muscle weakness, fatigue, vision changes, rash, or changes in urinary pattern.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bawaskar HS and Bawaskar PH, \"Efficacy and Safety of Scorpion Antivenom Plus Prazosin Compared With Prazosin Alone for Venomous Scorpion",
"      <i>",
"       (Mesobuthus tamulus)",
"      </i>",
"      Sting: Randomised Open Label Clinical Trial,\"",
"      <i>",
"       BMJ",
"      </i>",
"      , 2011, 342:c7136.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/21209062/pubmed\" id=\"21209062\" target=\"_blank\">",
"        21209062",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bosnak M, Levent Yilmaz H, Ece A, et al, \"Severe Scorpion Envenomation in Children: Management in Pediatric Intensive Care Unit,\"",
"      <i>",
"       Hum Exp Toxicol",
"      </i>",
"      , 2009, 28(11):721-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/19812121/pubmed\" id=\"19812121\" target=\"_blank\">",
"        19812121",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gupta BD, Parakh M, and Purohit A, \"Management of Scorpion Sting: Prazosin or Dobutamine,\"",
"      <i>",
"       J Trop Pediatr",
"      </i>",
"      , 2010, 56(2):115-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/19710245/pubmed\" id=\"19710245\" target=\"_blank\">",
"        19710245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Heart, Lung, and Blood Institute, \"Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents,\" Clinical Practice Guidelines, 2011, National Institutes of Health. Available at",
"      <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"       file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"      </a>",
"      . Accessed: March 16, 2012.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, \"The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2004, 114(2 Suppl 4th Report):555-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/15286277/pubmed\" id=\"15286277\" target=\"_blank\">",
"        15286277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sinaiko AR, &ldquo;Pharmacologic Management of Childhood Hypertension,&rdquo;",
"      <i>",
"       Pediatr Clin North Am",
"      </i>",
"      , 1993, 40(1):195-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/8417406 /pubmed\" id=\"8417406 \" target=\"_blank\">",
"        8417406",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tuuri RE and Reynolds S, \"Scorpion Envenomation and Antivenom Therapy,\"",
"      <i>",
"       Pediatr Emerg Care",
"      </i>",
"      , 2011, 27(7):667-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?29/20/30021/abstract-text/21730810/pubmed\" id=\"21730810\" target=\"_blank\">",
"        21730810",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12722 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-FE77A46CF4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30021=[""].join("\n");
var outline_f29_20_30021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212752\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055005\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054997\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212728\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212712\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055009\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055008\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212778\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212776\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055013\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054996\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15255518\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9838452\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212721\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055015\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212724\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13459610\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055004\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1054995\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055011\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055012\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1055002\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/16/23814?source=related_link\">",
"      Prazosin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/19/37172?source=related_link\">",
"      Prazosin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30022="Risk of infection in children with fever and non-chemotherapy-induced neutropenia";
var content_f29_20_30022=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Nabil M Ahmed, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Debra L Palazzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30022/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/20/30022/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever may be the first manifestation of a life-threatening infection in the neutropenic child, particularly one with a primary hematologic disease such as severe aplastic anemia or congenital neutropenia. Because of important differences between hematology and oncology patients with neutropenia, the risk of infection in hematology patients with different types of non-chemotherapy-induced neutropenia and fever are reviewed here. The management of fever and neutropenia in these patients and in children with chemotherapy-induced neutropenia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=see_link&amp;anchor=H23804302#H23804302\">",
"     \"Fever in children with chemotherapy-induced neutropenia\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, neutropenia is defined as an absolute neutrophil count (ANC) &lt;1500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The ANC is calculated using the following formula:",
"   </p>",
"   <p>",
"    ANC = total white blood cell count",
"    <span class=\"nowrap\">",
"     (cells/microL)",
"    </span>",
"    x (percent neutrophils + percent bands) &divide; 100",
"   </p>",
"   <p>",
"    Recognizing that the definition of a normal ANC varies with age and race is important. The lower limit of normal for the ANC in infants between two weeks and six months of age is lower than that for the older child",
"    <span class=\"nowrap\">",
"     (1000/microL",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     1500/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/1\">",
"     1",
"    </a>",
"    ]. Also, normal neutrophil values for people of African descent are lower than those for Caucasians [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of neutropenia is classified as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild &mdash; ANC 1000 to",
"      <span class=\"nowrap\">",
"       1500/microL",
"      </span>",
"     </li>",
"     <li>",
"      Moderate &mdash; ANC 500 to",
"      <span class=\"nowrap\">",
"       1000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Severe &mdash;ANC",
"      <span class=\"nowrap\">",
"       &lt;500/microL.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most studies evaluating the significance of the degree of neutropenia on the risk of infection have been in cancer patients, in whom an increased risk of infection becomes apparent at an ANC",
"    <span class=\"nowrap\">",
"     &lt;1000/microL,",
"    </span>",
"    is greater at",
"    <span class=\"nowrap\">",
"     &lt;500/microL,",
"    </span>",
"    and greatest at",
"    <span class=\"nowrap\">",
"     &lt;100/microL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the ANC, factors that influence a patient's susceptibility to infection include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duration of neutropenia",
"     </li>",
"     <li>",
"      Function of the neutrophils",
"     </li>",
"     <li>",
"      Ability of the bone marrow to respond to an infectious insult",
"     </li>",
"     <li>",
"      Function of other components of the immune system",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These factors contribute to the differences in infectious complications that are observed between hematology patients with neutropenia and cancer patients with therapy-induced neutropenia. For example, neutropenia in the oncology patient is related to cytotoxic therapy and generally is self-limited, whereas in the patient with severe aplastic anemia, neutropenia may be prolonged for months to years. However, the neutropenic oncology patient often has defects in several arms of the immune system because of the underlying disease",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemotherapeutic agents used, and these defects may not exist in the hematology patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FEVER AND NEUTROPENIA IN THE OTHERWISE HEALTHY CHILD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The afebrile child with the finding of isolated neutropenia may be followed with serial blood counts and examinations since, in most cases, the neutropenia arises in association with a viral infection and is transient, resolving in one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/4\">",
"     4",
"    </a>",
"    ]. Drugs, such as antibiotics and anticonvulsants, also can cause neutropenia that most often resolves after cessation of the drug. However, if such a child develops fever, or if a previously healthy child is found to have isolated neutropenia during a febrile illness, appropriate management requires consideration of the risk of serious bacterial infection. Such scenarios are not uncommon. In contrast to the wealth of studies in oncology patients with fever and neutropenia, only a few have been conducted in patients with non-chemotherapy-induced neutropenia.",
"   </p>",
"   <p>",
"    One retrospective study to establish the risk of infection was performed in 119 well-appearing children without underlying co-morbid illnesses who were found to be neutropenic, nine severely so, during minor acute illnesses, routine preoperative screening, or treatment for common childhood conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/5\">",
"     5",
"    </a>",
"    ]. No patients with neutropenia lasting less than 30 days developed infectious complications. Of the 36 patients found to be neutropenic for more than 30 days, only four (11 percent) developed infectious complications. The four infections were stomatitis (2), cellulitis (1), and pneumonia (1).",
"   </p>",
"   <p>",
"    Another retrospective study examined the outcomes of patients presumed to be immunocompetent who presented to a pediatric primary care clinic or pediatric emergency department with fever and newly identified moderate to severe neutropenia, leukopenia, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/6\">",
"     6",
"    </a>",
"    ]. This study found that leukopenia and neutropenia did not necessarily occur together. The prevalence of bacteremia was 5.5 percent, and while neither the degree of neutropenia nor leukopenia predicted bacteremia, nearly all bacteremic children were toxic-appearing at presentation. The prevalence of other infections was 14 percent, and the most common of these was pneumonia.",
"   </p>",
"   <p>",
"    These, albeit limited, observations suggest that the otherwise well-appearing child with isolated neutropenia and fever can be managed safely with age-appropriate treatment of any minor acute illness and frequent follow-up. However, any ill-appearing child with fever and neutropenia must be considered at risk for a serious bacterial infection and should receive empiric intravenous antibiotic therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H736498253#H736498253\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     INFECTION IN PATIENTS WITH SEVERE CHRONIC NEUTROPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient with severe chronic neutropenia presents a different problem from that of the well-appearing patient with transient neutropenia. Severe chronic neutropenia has multiple causes. Among the primary hematologic diagnoses are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic benign neutropenia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"       \"Immune neutropenia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Cyclic neutropenia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"       \"Cyclic neutropenia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Severe congenital neutropenia (infantile agranulocytosis or Kostmann syndrome) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"       \"Congenital neutropenia\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Aplastic anemia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"       \"Inherited aplastic anemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"       \"Acquired aplastic anemia in children and young adults\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The types and risk of infection vary among the conditions, as does the management in response to fever (",
"    <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Chronic autoimmune and idiopathic neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic neutropenia is defined as neutropenia lasting longer than eight weeks. The most common cause of chronic neutropenia in children is chronic benign neutropenia, which can be autoimmune or idiopathic. Autoimmune neutropenia typically occurs in infants 5 to 15 months of age; antineutrophil antibodies are characteristic, and spontaneous recovery occurs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/7\">",
"     7",
"    </a>",
"    ]. By contrast, chronic idiopathic neutropenia is seen more often in older children or adolescents and is less frequently associated with recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H4#H4\">",
"     \"Immune neutropenia\", section on 'Autoimmune neutropenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link&amp;anchor=H9#H9\">",
"     \"Immune neutropenia\", section on 'Chronic idiopathic neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite these differences, most patients with autoimmune or chronic idiopathic neutropenia have a benign course, as illustrated by the following data.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one natural history study conducted over a 13-year period, only 2 of 45 patients with chronic neutropenia of both idiopathic and autoimmune types had severe and recurrent infections [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/4\">",
"       4",
"      </a>",
"      ]. Upper respiratory tract infections, otitis media, and skin infections were relatively frequent in all of the patients. Among the 43 patients without severe and recurrent infections, 11 nevertheless had significant infections, including six girls with cellulitis or abscess of the labia (three of these infections were caused by Pseudomonas aeruginosa), three with recurrent gingivitis or mouth ulcers, and one each with periorbital cellulitis and pneumonia.",
"      <br/>",
"      <br/>",
"      Thirty-four patients (76 percent) experienced ANCs",
"      <span class=\"nowrap\">",
"       &lt;200/microL,",
"      </span>",
"      with occasional fluctuations into the normal range. All patients were treated with antibiotics during febrile episodes, usually by mouth. Hospitalizations other than for the initial evaluation were infrequent. Bone marrow was evaluated in 28 patients and demonstrated either normal or decreased numbers of neutrophils. Only three patients had maturation arrest at an early stage in myeloid maturation, and two of these were among the patients who suffered severe infectious complications.",
"     </li>",
"     <li>",
"      Similar rates of infection were observed in a separate study of 240 infants with autoimmune chronic neutropenia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/7\">",
"       7",
"      </a>",
"      ]. Minor infections developed in 90 percent of the patients despite severe neutropenia, whereas severe infections such as pneumonia, meningitis and sepsis developed in 12 percent. Most patients were followed for up to six years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that the majority of patients with either idiopathic or autoimmune chronic neutropenia generally have a benign course and do not require hospitalization and parenteral antibiotics for uncomplicated febrile illnesses. Patients with adequate marrow reserves most often can be treated appropriately with oral antibiotics and close outpatient management. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link&amp;anchor=H736498253#H736498253\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cyclic neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with cyclic neutropenia experience bouts of severe neutropenia, which last for three to six days, at approximately 21-day intervals. During these episodes they often have fevers, oral ulcers, gingivitis, periodontitis, pharyngitis, adenopathy, and malaise. Significant infections such as bacteremia, cellulitis, acute otitis media, sinusitis, pneumonia, or appendicitis occur less frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/9\">",
"     9",
"    </a>",
"    ]. Life-threatening illnesses, particularly necrotizing enterocolitis caused by Clostridium species [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/10,11\">",
"     10,11",
"    </a>",
"    ], may occur, although they are uncommon. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link&amp;anchor=H4#H4\">",
"     \"Cyclic neutropenia\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    To minimize oral complications, meticulous oral hygiene is important. Patients generally do not require antibiotics for the fevers or mucocutaneous inflammatory lesions that are typical during their neutrophil nadirs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/9\">",
"     9",
"    </a>",
"    ]. However, antibiotics should be administered if patients develop:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Uncharacteristic fever patterns",
"     </li>",
"     <li>",
"      Atypical oral lesions",
"     </li>",
"     <li>",
"      Significant infections such as acute otitis media, sinusitis, or lower respiratory tract infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complaints of abdominal pain should raise the possibility of Clostridium necrotizing enterocolitis. If this entity is suspected, the patient should be hospitalized and receive broad-spectrum antibiotics that include anaerobic coverage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prophylactic use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?43/27/44470?source=see_link\">",
"     granulocyte colony-stimulating factor",
"    </a>",
"    (G-CSF) can reduce the risk and severity of infection in patients with cyclic neutropenia. The use of G-CSF and the management of fever in these patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link&amp;anchor=H9#H9\">",
"     \"Cyclic neutropenia\", section on 'Granulocyte colony-stimulating factor'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Severe congenital neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike chronic benign neutropenia or cyclic neutropenia, severe congenital neutropenia (infantile agranulocytosis or Kostmann syndrome) presents shortly after birth with frequent and severe infections. Omphalitis, cellulitis, and perirectal abscesses are common during the first few months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/13\">",
"     13",
"    </a>",
"    ]. Disseminated infections, which may be life-threatening, are frequently caused by Staphylococcus aureus, Escherichia coli, and Pseudomonas sp. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H2#H2\">",
"     \"Congenital neutropenia\", section on 'Severe congenital neutropenia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the risk of serious infection, these patients should be evaluated and treated aggressively when febrile. Similar to its benefits in patients with cyclic neutropenia, the prophylactic use of G-CSF can reduce the risk and severity of infection in patients with severe congenital neutropenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H13#H13\">",
"     \"Congenital neutropenia\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the availability of platelet transfusions, infection has replaced bleeding as the major cause of death in patients with severe aplastic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"     \"Inherited aplastic anemia in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"     \"Acquired aplastic anemia in children and young adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A sentinel retrospective study reviewed the types of infections in 150 patients, including children, with aplastic anemia treated at the Clinical Hematology Branch of the National Heart, Lung and Blood Institute (NHLBI) between 1978 and 1990 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/14\">",
"     14",
"    </a>",
"    ]. By the end of the study period, 24 percent of patients died of infectious complications.",
"   </p>",
"   <p>",
"    Infection was documented microbiologically in 47 percent and clinically in another 22 percent of febrile episodes in this study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/14\">",
"     14",
"    </a>",
"    ]. The infected sites included the respiratory tract (32 percent), soft tissues (24 percent), blood (22 percent), gastrointestinal tract (17 percent), and urinary tract (6 percent).",
"   </p>",
"   <p>",
"    Among the pathogens identified, the vast majority were bacterial (67 percent), with fungal, viral, and parasitic accounting for 23, 7, and 3 percent, respectively. Gram-positive and gram-negative bacteria accounted for equal numbers of bacteremic episodes, with Staphylococcus epidermidis, Klebsiella pneumoniae, P. aeruginosa, S. aureus, and E. coli isolated most frequently. The majority of invasive fungal disease was caused by Aspergillus sp., followed by Candida sp. Ten of 11 Aspergillus infections were pulmonary. Although fungal organisms caused only 5 percent of primary infections, these pathogens accounted for 30 percent of secondary infections that arose during antibiotic therapy.",
"   </p>",
"   <p>",
"    The spectrum of pathogens isolated from these patients with aplastic anemia was similar to that observed in cancer patients with therapy-induced neutropenia. The major exception was the finding that Aspergillus sp. were the dominant fungi, which likely is due to the prolonged duration of neutropenia observed in many patients with aplastic anemia; Candida sp. are most common in cancer patients. These data indicate that patients with severe aplastic anemia and fever are at very high risk of serious infectious complications and must receive urgent evaluation and empiric antimicrobial therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"     \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar findings were reported in a retrospective analysis of the types of infections and outcomes in patients with aplastic anemia treated in a five-year interval between 1994 and 2000 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30022/abstract/15\">",
"     15",
"    </a>",
"    ]. One hundred four infectious events were documented in 42 patients (81 percent of the sample that ranged in age from 3 to 82 years). The number of severe infectious episodes was significantly higher in patients who were neutropenic. Fungal infections occurred only in neutropenic patients. Five patients in the study population died of infection. All of these patients had prolonged pancytopenia and invasive fungal infections, most of which were caused by molds. Four of the five patients who died also had bacterial coinfections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other bone marrow failure syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many syndromes, including Shwachman-Diamond syndrome, Fanconi anemia, dyskeratosis congenita, cartilage-hair hypoplasia and reticular dysgenesis, are associated with isolated neutropenia or bone marrow failure. The risk of infection caused by chronic profound neutropenia appears to be similar to that in patients with non-constitutional causes of severe aplastic anemia. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutropenia is defined as an absolute neutrophil count (ANC) &lt;1500",
"      <span class=\"nowrap\">",
"       cells/microL,",
"      </span>",
"      with mild, moderate, and severe neutropenia defined as an ANC of 1000 to",
"      <span class=\"nowrap\">",
"       1500/microL,",
"      </span>",
"      500 to",
"      <span class=\"nowrap\">",
"       1000/microL,",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       &lt;500/microL,",
"      </span>",
"      respectively. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of serious infection in otherwise healthy children with isolated transient neutropenia (eg, in the setting of a viral illness or in association with drugs such as antibiotics or anticonvulsants) is reflected in the general appearance of the child. Ill-appearing children are at greater risk for serious infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The well-appearing child can be managed safely with age-appropriate treatment of any minor acute illness and frequent follow-up. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fever and neutropenia in the otherwise healthy child'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The ill-appearing child should receive empiric intravenous antibiotic therapy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The risk and types of infection in children with fever and severe chronic neutropenia vary according to the underlying hematologic disorder (",
"      <a class=\"graphic graphic_table graphicRef65091 \" href=\"UTD.htm?40/8/41100\">",
"       table 1",
"      </a>",
"      ). The appropriate evaluation and specific management of these patients is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children with idiopathic or autoimmune chronic neutropenia have a low to moderate risk of infection. They often can be managed with appropriate oral antibiotic therapy and close outpatient follow-up. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=see_link\">",
"       \"Immune neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with cyclic neutropenia generally have a low to moderate risk of infection, but should receive antibiotics if they develop uncharacteristic fever patterns, atypical oral lesions, or recurrent or significant infections (eg, acute otitis media, sinusitis, or lower respiratory tract infection). Complaints of abdominal pain in addition to fever should prompt consideration of Clostridium necrotizing enterocolitis and may warrant hospitalization and broad-spectrum antibiotics, including coverage for anaerobic organisms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=see_link\">",
"       \"Cyclic neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Children with severe congenital neutropenia and aplastic anemia are at high risk for infection. They should undergo aggressive evaluation, hospitalization, and initiation of broad-spectrum antibiotics. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link&amp;anchor=H2#H2\">",
"       \"Congenital neutropenia\", section on 'Severe congenital neutropenia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=see_link\">",
"       \"Acquired aplastic anemia in children and young adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=see_link\">",
"       \"Inherited aplastic anemia in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=see_link\">",
"       \"Evaluation and management of fever in children with non-chemotherapy-induced neutropenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dallman PR. Neutropenia. In: Pediatrics, Rudolph AM (Ed), Appleton-Century-Crofts, New York 1977. p.1178.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/2\">",
"      Caramihai E, Karayalcin G, Aballi AJ, Lanzkowsky P. Leukocyte count differences in healthy white and black children 1 to 5 years of age. J Pediatr 1975; 86:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/3\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/4\">",
"      Jonsson OG, Buchanan GR. Chronic neutropenia during childhood. A 13-year experience in a single institution. Am J Dis Child 1991; 145:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/5\">",
"      Alario AJ, O'Shea JS. Risk of infectious complications in well-appearing children with transient neutropenia. Am J Dis Child 1989; 143:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/6\">",
"      Serwint JR, Dias MM, Chang H, et al. Outcomes of febrile children presumed to be immunocompetent who present with leukopenia or neutropenia to an ambulatory setting. Clin Pediatr (Phila) 2005; 44:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/7\">",
"      Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998; 91:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/8\">",
"      Dale DC, Guerry D 4th, Wewerka JR, et al. Chronic neutropenia. Medicine (Baltimore) 1979; 58:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/9\">",
"      Dale DC, Hammond WP 4th. Cyclic neutropenia: a clinical review. Blood Rev 1988; 2:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/10\">",
"      Hopkins DG, Kushner JP. Clostridial species in the pathogenesis of necrotizing enterocolitis in patients with neutropenia. Am J Hematol 1983; 14:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/11\">",
"      Bar-Joseph G, Halberthal M, Sweed Y, et al. Clostridium septicum infection in children with cyclic neutropenia. J Pediatr 1997; 131:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/12\">",
"      Weinberger M. Approach to management of fever and infection in patients with primary bone marrow failure and hemoglobinopathies. Hematol Oncol Clin North Am 1993; 7:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/13\">",
"      Kostman R. Infantile genetic agranulocytosis. A review with presentation of ten new cases. Acta Paediatr Scand 1975; 64:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/14\">",
"      Weinberger M, Elattar I, Marshall D, et al. Patterns of infection in patients with aplastic anemia and the emergence of Aspergillus as a major cause of death. Medicine (Baltimore) 1992; 71:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30022/abstract/15\">",
"      Torres HA, Bodey GP, Rolston KV, et al. Infections in patients with aplastic anemia: experience at a tertiary care cancer center. Cancer 2003; 98:86.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6058 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-2972EEEA2C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30022=[""].join("\n");
var outline_f29_20_30022=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H10\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FEVER AND NEUTROPENIA IN THE OTHERWISE HEALTHY CHILD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      INFECTION IN PATIENTS WITH SEVERE CHRONIC NEUTROPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Chronic autoimmune and idiopathic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Severe congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6058\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6058|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/8/41100\" title=\"table 1\">",
"      Neutropenic children infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3738?source=related_link\">",
"      Acquired aplastic anemia in children and young adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/61/42966?source=related_link\">",
"      Cyclic neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/3/20537?source=related_link\">",
"      Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/33/15898?source=related_link\">",
"      Fever in children with chemotherapy-induced neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/33/42520?source=related_link\">",
"      Immune neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/13/26842?source=related_link\">",
"      Inherited aplastic anemia in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30023="Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma";
var content_f29_20_30023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Jon C Aster, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Andrew Lister, MD, FRCP, FRCPath, FRCR",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30023/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/20/30023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H733536\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the REAL and WHO classification systems for hematologic malignancies, the lymphoblastic neoplasms, which may present as leukemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lymphoma, are divided into two general categories based upon lineage (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=see_link\">",
"     \"Classification of the hematopoietic neoplasms\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precursor B cell lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma,",
"      </span>",
"      also called precursor B cell acute lymphoblastic leukemia (precursor B cell ALL)",
"     </li>",
"     <li>",
"      Precursor T cell lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      (precursor T-LBL), also called precursor T cell acute lymphoblastic leukemia (precursor T cell ALL)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This is largely done because the prognosis and treatment differ between neoplasms of B and T cell lineage. These can be further divided into either lymphoblastic lymphoma or lymphoblastic leukemia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinically, a case is defined as lymphoma (LBL) if there is a mass lesion in the mediastinum or elsewhere and &lt;25 percent blasts in the bone marrow.",
"     </li>",
"     <li>",
"      It is classified as leukemia (ALL) if there are &gt;25 percent bone marrow blasts, with or without a mass lesion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Within each lineage group, there is significant biological and clinical overlap between neoplasms diagnosed as LBL and ALL. Although some patients present with predominantly lymphomatous involvement (eg, a mediastinal mass or another defined lesion), most have or later develop marrow involvement. Similarly, patients who present with leukemia may have or develop extramedullary tumors. Accordingly, lymphoblastic lymphoma and acute lymphoblastic leukemia should be considered the same disease with different clinical presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathobiology, diagnosis, and clinical presentation of precursor T lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    will be discussed here. The diagnosis of precursor B cell lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    and the treatment of these disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"     \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"     \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732696\">",
"    <span class=\"h1\">",
"     CELL OF ORIGIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor T-lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    (precursor T-LBL), also called precursor T cell acute lymphoblastic leukemia (precursor T cell ALL) is postulated to arise from precursor T lymphoblasts at varying stages of differentiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732703\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGIC DATA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    occurs most frequently in late childhood, adolescence, and young adulthood, with a 2:1 male predominance; it comprises 15 and 25 percent of childhood and adult ALL, respectively, and 2 percent of adult non-Hodgkin lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The incidence in the United States is approximately three cases per million persons per year and does not vary by ethnicity [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732710\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are usually males in their teens to early twenties who present with lymphadenopathy in cervical, supraclavicular, and axillary regions (50 percent), or with a mediastinal mass (50 to 75 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/9\">",
"     9",
"    </a>",
"    ]. In most patients the mediastinal mass is anterior, bulky, and associated with pleural effusions. These masses can produce such complications as superior vena cava syndrome, tracheal obstruction, and pericardial effusions (with or without tamponade). The disease tempo is variable with some patients presenting with symptoms progressing slowly over weeks to months and with others presenting more acutely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less commonly, patients present with extranodal disease (eg, skin, testicular, or bony involvement). Abdominal involvement is very unusual, but when it does occur it is found primarily in the liver and spleen.",
"   </p>",
"   <p>",
"    More than 80 percent of patients present with stage III or stage IV disease and almost 50 percent have B symptoms; in the majority, serum lactate dehydrogenase (LDH) levels are elevated. Although the bone marrow is frequently normal at presentation, approximately 60 percent of patients develop bone marrow infiltration and a subsequent leukemic phase indistinguishable from T cell ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation of the spinal fluid is essential to rule out central nervous system (CNS) involvement, which is frequently seen. Patients with bone marrow involvement have a particularly high incidence of CNS infiltration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H498078\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732717\">",
"    <span class=\"h2\">",
"     Morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;On peripheral blood smears, lymphoblasts vary from small cells with scant cytoplasm, condensed nuclear chromatin, and indistinct nucleoli to larger cells with moderate amounts of cytoplasm, dispersed chromatin, and multiple nucleoli. A few azurophilic cytoplasmic granules may be present. Auer rods are never seen.",
"   </p>",
"   <p>",
"    In tissue sections, the tumor cells are small to medium-sized, with scant cytoplasm, round, oval, or convoluted nuclei, fine chromatin and indistinct or small nucleoli (",
"    <a class=\"graphic graphic_picture graphicRef66820 \" href=\"UTD.htm?22/52/23367\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83243 \" href=\"UTD.htm?8/17/8471\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef83245 \" href=\"UTD.htm?16/54/17257\">",
"     picture 3",
"    </a>",
"    ). Occasional cases have larger cells. Precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    is morphologically indistinguishable from precursor B cell",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732724\">",
"    <span class=\"h2\">",
"     Immunophenotype and histochemistry",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL,",
"    </span>",
"    evaluation often includes both histochemistry and flow cytometry. On histochemistry, the blasts often show \"chunky\" positivity on periodic acid Schiff (PAS) staining, variable positivity for nonspecific esterase and sudan black B, and negativity for myeloperoxidase.",
"   </p>",
"   <p>",
"    On flow cytometry, the lymphoblasts are typically positive for CD7 and either surface or cytoplasmic CD3, and variably express CD2, CD5, CD1a, CD4",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    CD8 (",
"    <a class=\"graphic graphic_figure graphicRef83244 \" href=\"UTD.htm?19/39/20084\">",
"     figure 1",
"    </a>",
"    ). A subset of tumors is positive for CALLA (CD10). Only surface CD3 is entirely lineage-specific, and a panel of markers should be used to confirm the diagnosis. The stage of differentiation can then be determined by evaluation of a constellation of antigens (earliest to latest) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/4,11-18\">",
"     4,11-18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Early or pro-T - CD2, CD7, CD38 and cytoplasmic CD3 (30 percent)",
"     </li>",
"     <li>",
"      Common thymocyte - CD1a, sCD3,",
"      <span class=\"nowrap\">",
"       CD4/CD8",
"      </span>",
"      double positive (50 percent)",
"     </li>",
"     <li>",
"      Late thymocyte - CD4 or CD8 single positive (20 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is some correlation with presentation and differentiation stage (cases with bone marrow and blood presentation in general are arrested at earlier differentiation stage than cases with thymic presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]); however, there is significant overlap [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/21\">",
"     21",
"    </a>",
"    ]. In one report in children, no relationship was found between clinical outcome and maturational stage [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/22\">",
"     22",
"    </a>",
"    ], while in an adult study, the complete remission rate was significantly higher in those with the more mature T cell variants (91 versus 56 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 percent of T cell LBLs express the homing",
"    <span class=\"nowrap\">",
"     receptor/cell",
"    </span>",
"    adhesion molecule CD44. Expression of CD44 correlates with maturation, as",
"    <span class=\"nowrap\">",
"     CD4-/CD8-",
"    </span>",
"    tumors are CD44+ whereas",
"    <span class=\"nowrap\">",
"     CD4+/CD8+",
"    </span>",
"    tumors tend to be CD44-. CD10, on the other hand, correlates with lymphomatous presentation, as approximately 40 percent of T cell LBLs express CD10; by comparison, less than 10 percent of T cell ALLs are CD10+.",
"   </p>",
"   <p>",
"    Rare cases of LBL express antigens present on NK cells (CD16, CD57).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732731\">",
"    <span class=\"h2\">",
"     Genetic analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rearrangement of antigen receptor genes is variable in lymphoblastic neoplasms, and may not be lineage-specific; thus, precursor T cell neoplasms may have either or both T cell receptor (TCR) beta or gamma chain gene rearrangements and immunoglobulin heavy chain gene rearrangements [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/24\">",
"     24",
"    </a>",
"    ]. As such, immunophenotyping is used to determine T cell or B cell lineage.",
"   </p>",
"   <p>",
"    Chromosomal translocations involving the TCR alpha and delta loci at chromosome 14q11 and beta and gamma loci at 7q34 are present in about one-third of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]; the partner genes are variable and include the transcription factors c-MYC (8q24),",
"    <span class=\"nowrap\">",
"     TAL1/SCL",
"    </span>",
"    (1p32), RBTN1 (11p35), RBTN2 (11913), and HOX11 (10q24) and the cytoplasmic tyrosine kinase LCK (1p34). In an additional 25 percent, the TAL1 locus at 1p32 has deletions in the 5' regulatory region [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/27\">",
"     27",
"    </a>",
"    ]; together with translocations, rearrangements of TAL1 are the most common chromosomal aberration involving a proto-oncogene in T-ALL. Deletions of 9p involving deletion of the p16(ink4a) tumor suppressor gene (CDK4 inhibitor) are also seen in a high fraction of T-lymphoblastic neoplasms.",
"   </p>",
"   <p>",
"    A rare t(7;9)(7q34;9q34.3) involving the gene NOTCH1 is found in less than 1 percent of T-ALLs. Much more common are point mutations involving NOTCH1, which result in excessive activation of the NOTCH1 receptor. NOTCH1 is the most commonly mutated oncoprotein in T-ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/28\">",
"     28",
"    </a>",
"    ]. Recognition of NOTCH1 mutations has led to attempts to treat refractory T-ALL with NOTCH pathway inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One report found that 61 percent of pediatric patients had an abnormal karyotype, the most common abnormalities being del(6q) and 14q11 breakpoints. Other abnormalities included del(9p), trisomy 8, 11q23 breakpoints, 14q32 translocations, and 7q32-q36 breakpoints. In contrast to precursor B cell lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma,",
"    </span>",
"    cytogenetics are not of prognostic significance in the patients with T cell",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"   </p>",
"   <p>",
"    A more detailed discussion of chromosomal abnormalities in ALL is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"     \"Cytogenetics in acute lymphoblastic leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732738\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of precursor T-lymphoblastic",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    is made based upon the results of a bone marrow aspirate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    biopsy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    aspirate with or without biopsy of other involved tissues, such as the mediastinum. In addition to histological analysis, portions of the aspirated material or biopsy specimen should be sent for flow cytometry and cytogenetic evaluation (which should now be considered standard in all acute leukemias).",
"   </p>",
"   <p>",
"    Blasts are present in the peripheral blood, bone marrow, or tissue biopsy. Their morphology varies, but is identical in precursor T",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    and precursor B",
"    <span class=\"nowrap\">",
"     ALL/LBL.",
"    </span>",
"    In some instances, the blasts are so primitive that morphologic distinction from acute myeloid leukemia (AML) is difficult or impossible. Because antigen receptor gene rearrangements are not lineage specific, immunophenotype plays a key role in the diagnosis of precursor T",
"    <span class=\"nowrap\">",
"     LBL/ALL.",
"    </span>",
"   </p>",
"   <p>",
"    The blasts can be distinguished from the myeloblasts of acute myeloid leukemia (AML) by their positivity for TdT (",
"    <a class=\"graphic graphic_picture graphicRef83237 \" href=\"UTD.htm?29/25/30103\">",
"     picture 4",
"    </a>",
"    ) and lack of staining for myeloperoxidase. The T cell lineage is then identified by evaluation of a panel of T cell antigens, including CD3.",
"   </p>",
"   <p>",
"    The term precursor T cell acute lymphoblastic leukemia (T-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor T cell lymphoblastic lymphoma (T-LBL) is used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732745\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis for precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    includes other forms of lymphoma and leukemia. Most notably, precursor T cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    is differentiated from precursor B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    by immunophenotypic analysis, which demonstrates the presence of T cell antigens and the absence of B cell antigens. In addition, precursor T and B cell",
"    <span class=\"nowrap\">",
"     LBL/ALL",
"    </span>",
"    are differentiated from AML by their positivity for TdT and lack of staining for myeloperoxidase. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H732752\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of aggressive ALL-type therapy, this disease was rapidly fatal. Currently, children with T-ALL treated with such therapeutic regimens have outcomes similar to those of children with B-ALL. Treatment of precursor T-ALL is generally more aggressive than that for precursor B-ALL, and is the same for lymphomatous and leukemic presentations [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/30\">",
"     30",
"    </a>",
"    ]. Among adults, T-ALL has a more favorable outcome than B-lineage ALL. This may be related to younger patient age and lack of distinctive adverse cytogenetic abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=see_link\">",
"     \"Overview of the treatment of acute lymphoblastic leukemia in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Gene expression profiling and other studies have identified a number of genes associated with response to induction therapy and remission duration in T cell ALL [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/31\">",
"     31",
"    </a>",
"    ]. The profiles in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/32\">",
"     32",
"    </a>",
"    ] and children [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/33\">",
"     33",
"    </a>",
"    ] show some divergence, which might explain differences in outcomes of adults and children. On the other hand, adult chemotherapy regimens have not been as intensive as those used in children, and it remains possible that differences in therapy in adult and childhood T-ALL (as well as B-ALL) may at least in part explain worse outcomes in adults.",
"   </p>",
"   <p>",
"    Prognostic factors for T cell ALL were evaluated in 356 adult patients treated uniformly on the prospective trial UKALL",
"    <span class=\"nowrap\">",
"     XII/ECOG",
"    </span>",
"    2993, in which complete remission was observed in 94 percent and five-year overall survival was 48 percent. The following prognostic variables were described [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30023/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Survival was significantly shorter for females than males (41 versus 50 percent) and for those &gt;35 years of age (38 versus 52 percent).",
"     </li>",
"     <li>",
"      Positivity of blasts for CD1a and lack of expression of CD13 were associated with significantly better survival. Complex cytogenetic abnormalities were associated with a significantly poorer five-year survival (19 versus 51 percent).",
"     </li>",
"     <li>",
"      Patients with a matched sibling donor had significantly better five-year survival than those without such donors (61 versus 46 percent).",
"     </li>",
"     <li>",
"      The outcome following relapse was dismal, with only 8 of the 123 (6.5 percent) relapsed patients surviving at a median of 5.2 years. Six of the eight survivors had undergone allogeneic transplantation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is clear from these observations that disease relapse is a more common cause of death than failure to achieve complete remission. The pros and cons of hematopoietic cell transplantation for preventing relapse in ALL are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"     \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=see_link\">",
"       \"Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H733156\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Precursor T-lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      (precursor T-LBL), also called precursor T cell acute lymphoblastic leukemia (precursor T cell ALL) is postulated to arise from precursor T lymphoblasts at varying stages of differentiation.",
"     </li>",
"     <li>",
"      The term precursor T cell acute lymphoblastic leukemia (T-ALL) is used if there are &gt;25 percent bone marrow blasts, with or without a mass lesion. For cases with a mass lesion and less than 25 percent bone marrow involvement, the term precursor T cell lymphoblastic lymphoma (T-LBL) is used. (See",
"      <a class=\"local\" href=\"#H733536\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Precursor T cell",
"      <span class=\"nowrap\">",
"       LBL/ALL",
"      </span>",
"      occurs most frequently in late childhood, adolescence, and young adulthood, with a male predominance; it comprises 15 percent of childhood and 25 percent of adult ALL and 2 percent of adult non-Hodgkin lymphoma. (See",
"      <a class=\"local\" href=\"#H732703\">",
"       'Epidemiologic data'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Peripheral blood smear, bone marrow biopsy, and tissue biopsy can demonstrate lymphoblasts with varying morphology. Precursor T",
"      <span class=\"nowrap\">",
"       LBL/ALL",
"      </span>",
"      is morphologically indistinguishable from precursor B",
"      <span class=\"nowrap\">",
"       ALL/LBL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H732717\">",
"       'Morphology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Key diagnostic studies include histochemical stains, immunocytochemistry, and flow cytometry. These are required to differentiate among precursor",
"      <span class=\"nowrap\">",
"       T-ALL/LBL,",
"      </span>",
"      precursor",
"      <span class=\"nowrap\">",
"       B-ALL/LBL,",
"      </span>",
"      and other acute leukemias. (See",
"      <a class=\"local\" href=\"#H732724\">",
"       'Immunophenotype and histochemistry'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of genetic abnormalities have been identified in patients with precursor",
"      <span class=\"nowrap\">",
"       T-ALL/LBL,",
"      </span>",
"      but at present these are not prognostically important. (See",
"      <a class=\"local\" href=\"#H732731\">",
"       'Genetic analysis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"       \"Cytogenetics in acute lymphoblastic leukemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of precursor T-lymphoblastic",
"      <span class=\"nowrap\">",
"       leukemia/lymphoma",
"      </span>",
"      is made based upon the results of a bone marrow biopsy with or without biopsy of other involved tissues, such as the mediastinum. (See",
"      <a class=\"local\" href=\"#H732738\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Age at diagnosis and chromosomal abnormalities appear to be important prognostic factors. (See",
"      <a class=\"local\" href=\"#H732752\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/1\">",
"      Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/2\">",
"      Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/3\">",
"      Brouet JC, Rabian C, Gisselbrecht C, Flandrin G. Clinical and immunological study of non-Hodgkin T-cell lymphomas (cutaneous and lymphoblastic lymphomas excluded). Br J Haematol 1984; 57:315.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/5\">",
"      Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973-2003. Cancer Causes Control 2008; 19:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/6\">",
"      Boucheix C, David B, Sebban C, et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994; 84:1603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/7\">",
"      Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16:2780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/8\">",
"      Dores GM, Devesa SS, Curtis RE, et al. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood 2012; 119:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/9\">",
"      Streuli RA, Kaneko Y, Variakojis D, et al. Lymphoblastic lymphoma in adults. Cancer 1981; 47:2510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/10\">",
"      Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults. Blood 1995; 85:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/11\">",
"      Link MP, Stewart SJ, Warnke RA, Levy R. Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. J Clin Invest 1985; 76:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/12\">",
"      Nadler LM, Reinherz EL, Weinstein HJ, et al. Heterogeneity of T-cell lymphoblastic malignancies. Blood 1980; 55:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/13\">",
"      Weiss LM, Bindl JM, Picozzi VJ, et al. Lymphoblastic lymphoma: an immunophenotype study of 26 cases with comparison to T cell acute lymphoblastic leukemia. Blood 1986; 67:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/14\">",
"      Hollema H, Poppema S. T-lymphoblastic and peripheral T-cell lymphomas in the northern part of The Netherlands. An immunologic study of 29 cases. Cancer 1989; 64:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/15\">",
"      Cossman J, Chused TM, Fisher RI, et al. Diversity of immunological phenotypes of lymphoblastic lymphoma. Cancer Res 1983; 43:4486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/16\">",
"      Picozzi VJ Jr, Coleman CN. Lymphoblastic lymphoma. Semin Oncol 1990; 17:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/17\">",
"      Sheibani K, Nathwani BN, Winberg CD, et al. Antigenically defined subgroups of lymphoblastic lymphoma. Relationship to clinical presentation and biologic behavior. Cancer 1987; 60:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/18\">",
"      Medeiros LJ, Weiss LM, Picker LJ, et al. Expression of LFA-1 in non-Hodgkin's lymphoma. Cancer 1989; 63:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/19\">",
"      Bernard A, Boumsell L, Reinherz EL, et al. Cell surface characterization of malignant T cells from lymphoblastic lymphoma using monoclonal antibodies: evidence for phenotypic differences between malignant T cells from patients with acute lymphoblastic leukemia and lymphoblastic lymphoma. Blood 1981; 57:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/20\">",
"      Gouttefangeas C, Bensussan A, Boumsell L. Study of the CD3-associated T-cell receptors reveals further differences between T-cell acute lymphoblastic lymphoma and leukemia. Blood 1990; 75:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/21\">",
"      Quintanilla-Martinez L, Zukerberg LR, Harris NL. Prethymic adult lymphoblastic lymphoma. A clinicopathologic and immunohistochemical analysis. Am J Surg Pathol 1992; 16:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/22\">",
"      Crist WM, Shuster JJ, Falletta J, et al. Clinical features and outcome in childhood T-cell leukemia-lymphoma according to stage of thymocyte differentiation: a Pediatric Oncology Group Study. Blood 1988; 72:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/23\">",
"      Vitale A, Guarini A, Ariola C, et al. Adult T-cell acute lymphoblastic leukemia: biologic profile at presentation and correlation with response to induction treatment in patients enrolled in the GIMEMA LAL 0496 protocol. Blood 2006; 107:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/24\">",
"      Szczepa��ski T, Pongers-Willemse MJ, Langerak AW, et al. Ig heavy chain gene rearrangements in T-cell acute lymphoblastic leukemia exhibit predominant DH6-19 and DH7-27 gene usage, can result in complete V-D-J rearrangements, and are rare in T-cell receptor alpha beta lineage. Blood 1999; 93:4079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/25\">",
"      Khalidi HS, Chang KL, Medeiros LJ, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol 1999; 111:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/26\">",
"      Uckun FM, Sensel MG, Sun L, et al. Biology and treatment of childhood T-lineage acute lymphoblastic leukemia. Blood 1998; 91:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/27\">",
"      Begley CG, Green AR. The SCL gene: from case report to critical hematopoietic regulator. Blood 1999; 93:2760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/28\">",
"      Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/29\">",
"      Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol 2008; 3:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/30\">",
"      Goldberg JM, Silverman LB, Levy DE, et al. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21:3616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/31\">",
"      Baldus CD, Burmeister T, Martus P, et al. High expression of the ETS transcription factor ERG predicts adverse outcome in acute T-lymphoblastic leukemia in adults. J Clin Oncol 2006; 24:4714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/32\">",
"      Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 2002; 1:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/33\">",
"      Chiaretti S, Li X, Gentleman R, et al. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004; 103:2771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30023/abstract/34\">",
"      Marks DI, Paietta EM, Moorman AV, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood 2009; 114:5136.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15773 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-FB51BAF4EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30023=[""].join("\n");
var outline_f29_20_30023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H733156\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H733536\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732696\">",
"      CELL OF ORIGIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732703\">",
"      EPIDEMIOLOGIC DATA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732710\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H498078\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732717\">",
"      Morphology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732724\">",
"      Immunophenotype and histochemistry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H732731\">",
"      Genetic analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732738\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732745\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H732752\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H733156\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/15773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15773|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/39/20084\" title=\"figure 1\">",
"      Flow T cell ALL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/15773|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?22/52/23367\" title=\"picture 1\">",
"      Lymphoblastic lymphoma High",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/17/8471\" title=\"picture 2\">",
"      BM aspirate T cell ALL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17257\" title=\"picture 3\">",
"      Lymph node T cell LBL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/25/30103\" title=\"picture 4\">",
"      TdT staining ALL",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/53/21337?source=related_link\">",
"      Classification of the hematopoietic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=related_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=related_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=related_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/6/31850?source=related_link\">",
"      Overview of the treatment of acute lymphoblastic leukemia in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/34/17955?source=related_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30024="Driving restrictions in patients with an implantable cardioverter-defibrillator";
var content_f29_20_30024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Driving restrictions in patients with an implantable cardioverter-defibrillator",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Tatjana N Sljapic, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?29/20/30024/contributors\">",
"     Brian C Downey, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?29/20/30024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 28, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The implantable cardioverter-defibrillator (ICD) improves survival in patients who have been resuscitated from ventricular fibrillation or unstable ventricular tachycardia (ie, secondary prevention of sudden cardiac death). Compelling data indicate that the ICD is also effective in the primary prevention of sudden cardiac death (SCD) in select high risk patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most ICD candidates are ambulatory and appear well enough to drive an automobile. However, due to the risks of ventricular arrhythmias and ICD shocks, there are concerns about the risks associated with driving in this population. This topic will review issues related to driving in patients with an ICD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CONCERNS WITH DRIVING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concerns about driving center on the risk of symptomatic ventricular tachyarrhythmias",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ICD discharge. More specifically, the risks associated with driving are based upon the likelihood that such events could impair consciousness and the patient's ability to control the vehicle. Driving, therefore, carries risk for the patient, other occupants of the vehicle, and persons outside of the vehicle. The extension of risk to others makes this issue a public health concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms of risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both ventricular arrhythmias and the actions of the ICD itself can potentially interfere with driving by several mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sudden death &mdash; Although ICDs improve survival, they do not eliminate risk of SCD. Data from major trials indicate that the rate of SCD among patients who receive an ICD for secondary prevention is one to two percent per year [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Similar or slightly lower SCD rates have been reported in major primary prevention trials [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/4-6\">",
"       4-6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Syncope &mdash; Even rapid treatment of a ventricular arrhythmia by an ICD may not protect against driving impairment, since syncope or altered states of consciousness can still occur. In a review of 421 ICD patients, for example, syncope occurred in approximately 15 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"       7",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Syncope'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Transient incapacitation from the shock &mdash; Even if therapy is successful and the patient remains conscious, an ICD discharge, either appropriate or inappropriate, may startle or briefly incapacitate the patient and disrupt safe motor vehicle operation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Overall incidence of ventricular arrhythmias and ICD shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among the first issues to consider when evaluating the patient is the overall incidence of ventricular arrhythmias and ICD shocks in patients with these devices. Although this information does not directly translate into risks associated with driving, it does provide a general sense of the likelihood of such an event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     In patients treated for secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of recurrent ventricular arrhythmias and ICD therapies among patients treated with an ICD for secondary prevention is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 299 patients, over an average follow-up of 10 months, 66,000 episodes of VT or VF occurred in 281 patients (236 per patient) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/8\">",
"       8",
"      </a>",
"      ]. The arrhythmia terminated spontaneously in 74 percent, after antitachycardia pacing in 22 percent, and after a shock in only",
"      <strong>",
"       1.7 percent",
"      </strong>",
"      (four per patient). Inappropriate discharges, due to supraventricular tachyarrhythmias, electrical noise, or other cause, occurred in 92 patients (23 percent).",
"     </li>",
"     <li>",
"      In the AVID trial, among the 449 patients assigned to ICD therapy, the proportion of patients with an arrhythmic event (arrhythmic death, sustained ventricular arrhythmia, shock or antitachycardia pacing) was 35 percent at three months, 53 percent at one year, and 68 percent at two years (",
"      <a class=\"graphic graphic_figure graphicRef69994 \" href=\"UTD.htm?36/35/37437\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/9\">",
"       9",
"      </a>",
"      ]. First shocks or antitachycardia pacing after the second year were uncommon.",
"     </li>",
"     <li>",
"      Several additional studies noted a similar incidence of appropriate early therapy for VT or VF (eg, 33 to 46 percent of patients at one year and 55 percent at 15 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/10-13\">",
"       10-13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a related concern, among patients treated with an ICD for secondary prevention, one device therapy seems to suggest an increased risk of additional events in the next year. In an illustrative series, the mean time to first ICD therapy was 138 days; among those with a first event, the mean time to second ICD therapy was only 66 days [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients with an initial ICD therapy had a 79 percent likelihood of another ICD therapy within one year.",
"   </p>",
"   <p>",
"    Patients who do not have an ICD therapy within the first year appear to have a lower, but still appreciable, risk of future events [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/10,14\">",
"     10,14",
"    </a>",
"    ]. One report, for example, identified 14 patients who had not received an appropriate shock at 24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/10\">",
"     10",
"    </a>",
"    ]. The actuarial risk of an appropriate shock in the next 24 months was 29 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     In patients treated for primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Earlier primary prevention ICD trials reported device discharge rates were as high as 50 percent in one year and 60 percent in two years [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/4,15\">",
"     4,15",
"    </a>",
"    ]. However, lower rates of ICD discharges (about 7 to 8 percent per year) were observed in later trials [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Predictors of events",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of clinical features are associated with an increased risk of arrhythmic events and ICD therapies. These include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduced LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12,17,18\">",
"       12,17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      New York Heart Association Functional Class III or IV heart failure [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12,18,19\">",
"       12,18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sustained monomorphic VT rather than VF as the presenting arrhythmia [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12,18\">",
"       12,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of revascularization in patients with coronary heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12,18\">",
"       12,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Absence of beta blocker therapy after hospital discharge [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/12,18\">",
"       12,18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;When considering the risks associated with driving by patients with ICDs, the incidence of ventricular arrhythmias and ICD discharge are actually less important than the incidence of syncope during an arrhythmic event (since not all events result in syncope or impaired consciousness).The incidence of syncope among patients treated with an ICD for secondary prevention ranges from 15 to 46 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7,12,20,21\">",
"     7,12,20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency, causes of, and risk factors for syncope were evaluated in a review of 421 patients with an ICD for secondary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"     7",
"    </a>",
"    ]. At a mean follow-up of 26 months, 62 had syncope (15 percent of all patients and 27 percent of those with recurrent ventricular arrhythmia). Syncopal episodes occurred in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Shortly after rapid and successful delivery of a first 34 joule shock; the mean ICD capacitor charge time was 9.4 sec (55 percent of syncopal episodes)",
"     </li>",
"     <li>",
"      VT that was initially treated with antitachycardia pacing, often in association with acceleration of the VT during pacing (16 percent of episodes)",
"     </li>",
"     <li>",
"      Incessant or clusters of VT (8 percent)",
"     </li>",
"     <li>",
"      Failure of a first shock (7 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No cause could be identified in three patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Risk factors for syncope",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical features predict an increased likelihood of syncope in patients treated with an ICD, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Syncope during a prior episode of VT [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7,22\">",
"       7,22",
"      </a>",
"      ]. In one series, among ICD patients with syncope during a prior episode of VT, the median time to a first recurrent syncopal event was 376 days, suggesting that, in patients who present with syncope and VT, the standard six month driving restriction may be inadequate [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Very rapid VT (cycle length less than 300 msec) [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A low LVEF [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Chronic atrial fibrillation [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The authors suggested that these risk factors may be used to risk-stratify ICD patients for future syncopal events. In the study discussed above, overall actuarial survival free of syncope was 90, 85, and 81 percent at one, two, and three years after implantation; in comparison, event-free survival was better in patients with none of the above risk factors (96, 92, and 92 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Potential benefit of antiarrhythmic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of recurrent syncope may be reduced by antiarrhythmic drugs, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . Antiarrhythmics can both prevent recurrent arrhythmias and slow the rate of recurrent VT, thereby increasing the likelihood that the arrhythmia will be hemodynamically tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Significance of device charge time",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modern high-energy ICDs are designed to improve the likelihood of effective defibrillation with increased energy delivery. Although charge times are slightly shorter with modern devices, charging the device to higher energies may still delay the initial shock by several seconds. The risk of syncope may be minimized with shorter ICD charge times.",
"   </p>",
"   <p>",
"    The most effective way to reduce charge times is to program initial therapies to be delivered at a lower energy (eg, 20 as opposed to 30 joules) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/23\">",
"     23",
"    </a>",
"    ]. Lower energy initial therapies can only be used in patients whose defibrillation thresholds are low. Attempts to reduce charge times may be limited in patients who are also treated with antiarrhythmic drugs, since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    increases the defibrillation threshold. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H19#H19\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Defibrillation threshold'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Inappropriate ICD shocks",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inappropriate shocks, which may predispose to an accident by startling or briefly incapacitating the patient, occur in 15 to 25 percent of patients with an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/8,9,24,25\">",
"     8,9,24,25",
"    </a>",
"    ]. The main cause is supraventricular tachyarrhythmia, including sinus tachycardia and atrial fibrillation. Such patients may become quite uncomfortable since multiple inappropriate shocks are often delivered with supraventricular tachyarrhythmias. Other causes of inappropriate shocks include electrical noise and ICD malfunction (eg, lead fracture) or inappropriate sensing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=see_link\">",
"     \"Implantable cardioverter-defibrillators: Complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional programming and dual chamber devices can reduce the frequency of inappropriate shocks for supraventricular tachyarrhythmia. Other alternatives include antiarrhythmic drugs and catheter ablation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=see_link&amp;anchor=H27332059#H27332059\">",
"     \"General principles of the implantable cardioverter-defibrillator\", section on 'Supraventricular tachyarrhythmias (including sinus tachycardia and atrial fibrillation) discrimination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     INCIDENCE OF ICD SHOCKS WHILE DRIVING AND ACCIDENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although information regarding the general incidence of arrhythmic events and the risk factors for such events are useful, there is now increasing evidence that directly addresses the incidence of such events while driving.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     ICD shocks while driving",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of ICD shocks associated was assessed in an analysis from the TOVA study [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/26\">",
"     26",
"    </a>",
"    ]. A total of 1,188 patients treated with an ICD for a range of primary and secondary prevention indications were followed for a median of 562 days. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The estimated risk of an ICD shock within one hour of driving was one shock per 25,000 person-hours of driving.",
"     </li>",
"     <li>",
"      The relative risk for ICD shocks for",
"      <span class=\"nowrap\">",
"       VT/VF",
"      </span>",
"      within one hour of driving compared to other times was 2.24. However, the elevated risk was limited to the 30 minutes after driving (relative risk 4.46 compared to other times), rather than during the driving episode itself (relative risk 1.05 compared to other times).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Accidents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among ICD patients, the actual incidence of motor vehicle accidents associated with device therapies and ventricular arrhythmias appears to be low. This issue was addressed in a study in which 452 physicians involved in ICD implantation and follow-up were surveyed regarding their recommendations to patients about driving and their experience regarding the number of fatal and nonfatal accidents caused by patients with an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/27\">",
"     27",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thirty motor vehicle accidents related to ICD shocks were identified over a 12 year period, resulting in nine deaths (eight patients and one passenger in a car driven by a patient). The 21 nonfatal accidents involved 15 patients, three passengers, and three bystanders.",
"     </li>",
"     <li>",
"      Less than 1 percent of ICD shocks occurred during driving. Among the 286 defibrillator discharges that occurred during driving, 30 (10.5 percent) resulted in accidents.",
"     </li>",
"     <li>",
"      The total fatality rate was statistically lower than the general population fatality rate (7.5 versus",
"      <span class=\"nowrap\">",
"       18.4/100,000",
"      </span>",
"      patient years). This was probably due to modifications in driving behavior by patients with an ICD. Only one-half of 82 patients surveyed continued to drive [",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/28\">",
"       28",
"      </a>",
"      ]. These patients spent comparatively little time driving, as 29 percent stopped driving on the highways, 29 percent drove only with their spouse, and 71 percent drove short distances and only when absolutely necessary.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One limitation of these observations is a possible reporting bias. Physicians with ICD patients who had been involved in a motor vehicle accident might have been reluctant to report this in a survey. Similarly, patients who have an accident may be reluctant to tell their physicians.",
"   </p>",
"   <p>",
"    A low rate of accidents has also been noted in other studies [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. A report from the AVID trial evaluated 627 patients who were drivers before their arrhythmia, who were treated with either an ICD or antiarrhythmic drugs, and who completed a questionnaire a median of nine months after entry into the trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/29\">",
"     29",
"    </a>",
"    ]. The following frequency of events while driving was noted:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Syncope - 2 percent",
"     </li>",
"     <li>",
"      Dizziness or palpitations necessitating stopping the vehicle - 11 percent",
"     </li>",
"     <li>",
"      Dizziness or palpitations, without the need to stop driving - 22 percent",
"     </li>",
"     <li>",
"      ICD shock - 8 percent",
"     </li>",
"     <li>",
"      Accidents preceded by symptoms suggesting an arrhythmia - 0.4 percent per patient-year, (compared to the accident rate in the general driving population of 0.7 percent per year). (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Adherence'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, despite the high frequency of arrhythmic events and despite the high frequency of patients resuming driving earlier than the recommended six months after implantation (78 percent of patients resumed within six months, 57 percent within three months), the incidence of accidents was low. Reporting bias is again a potential problem as patients may underreport accidents or near-accidents.",
"   </p>",
"   <p>",
"    A mathematical expression of the yearly risk of harm to other road users caused by a patient who develops loss of consciousness due to ventricular arrhythmia has been proposed by the Canadian Cardiovascular Society [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Risk of harm &nbsp;= &nbsp;TD &nbsp;x V &nbsp;x &nbsp;SCI &nbsp;x &nbsp;Ac",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    where TD = the time the patient spends driving a car; V = a constant based upon the type of vehicle driven (1.0 for a commercial vehicle and 0.28 for a standard-size passenger car); SCI = the risk of sudden death or incapacity during the year; and Ac = the probability that SCI will result in a death or injury.",
"   </p>",
"   <p>",
"    Based upon data from previous reports and the above equation, it has been suggested the annual risk of harm to other drivers and passersby by drivers with an ICD is 1 in 45,000 [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/32\">",
"     32",
"    </a>",
"    ]. Since most arrhythmic episodes occur in the first year (",
"    <a class=\"graphic graphic_figure graphicRef69994 \" href=\"UTD.htm?36/35/37437\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/9\">",
"     9",
"    </a>",
"    ], the risk should decrease over time. One report estimated the rate of accidents in patients with an ICD as 1 in 43,000 the first year, 1 in 83,000 in the second year, and 1 in 111,000 in the third year [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"     7",
"    </a>",
"    ]. The values were lower in lower risk patients (LVEF &gt;40 percent, no chronic atrial fibrillation, and no inducible rapid VT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding observations are consistent with the conclusion that, although restricting driving for a short period of time after ICD implantation may be necessary, excessive restrictions or a total ban may be unwarranted [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/27,30\">",
"     27,30",
"    </a>",
"    ]. At the present time, most physicians permit ICD recipients to drive at a mean of 7.3 months after implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The number of arrhythmic events patients experience, the presence or absence of syncope, the LVEF (a low value is a powerful predictor of an increased risk of arrhythmias), and antiarrhythmic drug treatment are some of the factors considered in the decision to resume driving. In addition, all reversible factors that might cause or exacerbate ventricular arrhythmia should be corrected (eg, coronary ischemia, drug toxicity, and electrolyte imbalance, particularly hypokalemia or hypomagnesemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Guidelines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Secondary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for driving after an episode of SCD have been published by the American Heart Association and North American Society for Pacing and Electrophysiology",
"    <span class=\"nowrap\">",
"     (AHA/NASPE),",
"    </span>",
"    the European Society of Cardiology (ESC), and the Canadian Consensus Development Conference [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/31-34\">",
"     31-34",
"    </a>",
"    ]. The 1996",
"    <span class=\"nowrap\">",
"     AHA/NASPE",
"    </span>",
"    recommendations, which are independent of whether the patient is treated with an ICD or antiarrhythmic drugs are summarized in Table 1 (",
"    <a class=\"graphic graphic_table graphicRef63519 \" href=\"UTD.htm?29/40/30348\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noncommercial drivers should not drive for the first six months postimplantation, the time of greatest risk for recurrent events (",
"      <a class=\"graphic graphic_figure graphicRef69994 \" href=\"UTD.htm?36/35/37437\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/9\">",
"       9",
"      </a>",
"      ]. If there has been no discharge from the ICD during this period, driving can be resumed.",
"     </li>",
"     <li>",
"      If highway or long-distance travel is anticipated, patients should be encouraged to have an adult companion drive and cruise control driving should be avoided.",
"     </li>",
"     <li>",
"      The six month driving restriction",
"      <strong>",
"       restarts",
"      </strong>",
"      if an ICD discharge occurs with or without syncope.",
"     </li>",
"     <li>",
"      For commercial drivers, the risk of harm to other road users as a consequence of ICD discharge or syncope is much higher. As a result, it was recommended that all commercial driving be prohibited permanently after a life-threatening ventricular arrhythmia whether the patient is treated with an ICD or antiarrhythmic drugs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients with an ICD have frequent episodes of hemodynamically well tolerated, asymptomatic VT that are consistently terminated (and without acceleration) by antitachycardia pacing. The guidelines recommend that decisions on noncommercial driving in such patients be made on a case by case basis.",
"   </p>",
"   <p>",
"    The 1997 ESC guidelines reached similar conclusions (",
"    <a class=\"graphic graphic_table graphicRef54246 \" href=\"UTD.htm?34/44/35532\">",
"     table 2",
"    </a>",
"    ), although it was emphasized that, because of limited data, the recommendations do not represent practice standards [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/33\">",
"     33",
"    </a>",
"    ]. Thus, clinical judgment should be considered with a given patient.",
"   </p>",
"   <p>",
"    However, some have considered these guidelines too conservative in light of subsequently published data and advances in the treatment of arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/35\">",
"     35",
"    </a>",
"    ]. In a report from the AVID trial described above, 57 percent of patients resumed driving within three months; the rate of patient-reported accidents preceded by symptoms suggestive of an arrhythmia was only 0.4 percent per patient-year, which is less than the accident rate in the general driving population (0.7 percent per year) [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/29\">",
"     29",
"    </a>",
"    ]. Patients in the AVID registry who were not randomized had similar clinical characteristics to those who were, suggesting that these observations can be generalized to all patients who would be eligible [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/36\">",
"     36",
"    </a>",
"    ]. Reporting bias is a potential problem since patients may underreport accidents or near-accidents.",
"   </p>",
"   <p>",
"    These observations have led to the suggestion that low-risk patients (LVEF &gt;40 percent, no persistent medical condition predisposing to recurrent arrhythmia, and no recurrent ventricular arrhythmia) can begin driving after three months [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, patients with frequent ICD shocks for recurrent arrhythmia may benefit from antiarrhythmic drug therapy, usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=see_link&amp;anchor=H7#H7\">",
"     \"Pharmacologic therapy in survivors of sudden cardiac arrest\", section on 'Adjunctive therapy in patients with an ICD'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Primary prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2007 addendum to the",
"    <span class=\"nowrap\">",
"     AHA/NASPE",
"    </span>",
"    guidelines provided the following driving recommendations for patients with ICDs implanted for primary prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noncommercial driving should be restricted for at least one week following ICD implantation. In the absence of symptoms potentially related to an arrhythmia, driving privileges thereafter should not be restricted.",
"     </li>",
"     <li>",
"      Patients should be instructed that impairment of consciousness is a possible future event.",
"     </li>",
"     <li>",
"      Patients who have received an ICD for primary prevention who subsequently receive an appropriate therapy for VT or VF, especially with symptoms of cerebral hypoperfusion, should be managed according to the recommendations for patients with ICDs for secondary prevention.",
"     </li>",
"     <li>",
"      These recommendations do not apply to the licensing of commercial drivers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ESC guidelines recommended no restriction for noncommercial driving but total restriction for commercial driving when an ICD was implanted for primary prevention (",
"    <a class=\"graphic graphic_table graphicRef54246 \" href=\"UTD.htm?34/44/35532\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/33\">",
"     33",
"    </a>",
"    ]. As in low-risk patients who receive an ICD for secondary prevention, resumption of driving may be safe after three months in patients who receive an ICD for primary prevention if they have had no sustained ventricular tachyarrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Nonsustained and hemodynamically tolerated ventricular arrhythmias without an ICD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 1996",
"    <span class=\"nowrap\">",
"     AHA/NASPE",
"    </span>",
"    guidelines also made recommendations for driving in patients with ventricular tachyarrhythmias (nonsustained VT and idiopathic VT) not associated with loss of consciousness (",
"    <a class=\"graphic graphic_table graphicRef63519 \" href=\"UTD.htm?29/40/30348\">",
"     table 1",
"    </a>",
"    ) not treated with ICDs [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No restrictions for either noncommercial or commercial driving for patients with nonsustained VT without impaired consciousness.",
"     </li>",
"     <li>",
"      Noncommercial driving should be restricted for three months and commercial driving for six months in patients with nonsustained VT and impaired consciousness or with idiopathic VT (ie, no apparent structural heart disease) without impaired consciousness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=see_link\">",
"       \"Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite these guidelines, many patients resume driving earlier than recommended. The frequency with which this occurs was illustrated in the report from the AVID trial discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/29\">",
"     29",
"    </a>",
"    ]. Of the 627 patients who were drivers before their index arrhythmia, 57 percent resumed driving within three months and 78 percent within six months. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Accidents'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patient adherence to driving restrictions was also assessed in a series of patients from the DAVID trial [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/37\">",
"     37",
"    </a>",
"    ]. A subset of the enrolled population, including 418 patients, were sent driving questionnaires, and 278 responded. The percentages of patients who had resumed driving at three, six, and nine months after implantation were 45, 67, and 88 percent, respectively. In this series, the duration that a patient abstained from driving correlated with the recommendation of the doctor or nurse at the time of ICD implantation.",
"   </p>",
"   <p>",
"    Similar findings were noted in a survey from Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/33\">",
"     33",
"    </a>",
"    ]. Despite medical advice, most patients resumed driving within six months and fatal accidents or ICD shocks while driving were rare. Lack of compliance with recommended driving restriction has also been noted in patients with syncope [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     State laws",
"    </span>",
"    &nbsp;&mdash;&nbsp;Legal restrictions on driving for patients with a history of cardiac arrhythmias, nonseizure, and seizure syncope differ among states and there is generally no distinction between patients managed medically or with an ICD [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/21\">",
"     21",
"    </a>",
"    ]. It has been estimated that, as of 1992, only about 30 percent of physicians who implanted an ICD were aware of state regulations regarding driving [",
"    <a class=\"abstract\" href=\"UTD.htm?29/20/30024/abstract/27\">",
"     27",
"    </a>",
"    ]. Furthermore, among those aware of state regulations, 20 percent admitted to making recommendations that were not consistent with the regulations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Discussion with patients and family members",
"    </span>",
"    &nbsp;&mdash;&nbsp;When making therapeutic decisions for life-threatening ventricular arrhythmias, the physician should make it clear to the patient and family members that driving restrictions are independent of whether the patient is treated with an ICD or antiarrhythmic drugs. Such discussions can be difficult because of the importance of driving for both independence and quality of life. It may be helpful for the physician to point out that the issue affects public safety as well as patient safety and that state law may both mandate driving restrictions and impose responsibility for accidents on a nonreporting physician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=see_link\">",
"       \"Patient information: Time to stop driving? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"       \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H632730791\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to thank Dr. David Bharucha, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/1\">",
"      Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Am Coll Cardiol 1999; 34:1552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/2\">",
"      Grubman EM, Pavri BB, Shipman T, et al. Cardiac death and stored electrograms in patients with third-generation implantable cardioverter-defibrillators. J Am Coll Cardiol 1998; 32:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/3\">",
"      Mitchell LB, Pineda EA, Titus JL, et al. Sudden death in patients with implantable cardioverter defibrillators: the importance of post-shock electromechanical dissociation. J Am Coll Cardiol 2002; 39:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/4\">",
"      Moss AJ, Hall WJ, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators. N Engl J Med 1996; 335:1933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/5\">",
"      Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350:2151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/6\">",
"      Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004; 351:2481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/7\">",
"      B&auml;nsch D, Brunn J, Castrucci M, et al. Syncope in patients with an implantable cardioverter-defibrillator: incidence, prediction and implications for driving restrictions. J Am Coll Cardiol 1998; 31:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/8\">",
"      Wood MA, Stambler BS, Damiano RJ, et al. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group. J Am Coll Cardiol 1994; 24:1692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/9\">",
"      Klein RC, Raitt MH, Wilkoff BL, et al. Analysis of implantable cardioverter defibrillator therapy in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial. J Cardiovasc Electrophysiol 2003; 14:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/10\">",
"      Fogoros RN, Elson JJ, Bonnet CA. Actuarial incidence and pattern of occurrence of shocks following implantation of the automatic implantable cardioverter defibrillator. Pacing Clin Electrophysiol 1989; 12:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/11\">",
"      Bardy GH, Hofer B, Johnson G, et al. Implantable transvenous cardioverter-defibrillators. Circulation 1993; 87:1152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/12\">",
"      Freedberg NA, Hill JN, Fogel RI, et al. Recurrence of symptomatic ventricular arrhythmias in patients with implantable cardioverter defibrillator after the first device therapy: implications for antiarrhythmic therapy and driving restrictions. CARE Group. J Am Coll Cardiol 2001; 37:1910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/13\">",
"      Nunain SO, Roelke M, Trouton T, et al. Limitations and late complications of third-generation automatic cardioverter-defibrillators. Circulation 1995; 91:2204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/14\">",
"      Curtis JJ, Walls JT, Boley TM, et al. Time to first pulse after automatic implantable cardioverter defibrillator implantation. Ann Thorac Surg 1992; 53:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/15\">",
"      Bigger JT Jr. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. N Engl J Med 1997; 337:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/16\">",
"      Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/17\">",
"      Larsen GC, Stupey MR, Walance CG, et al. Recurrent cardiac events in survivors of ventricular fibrillation or tachycardia. Implications for driving restrictions. JAMA 1994; 271:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/18\">",
"      Levine JH, Mellits ED, Baumgardner RA, et al. Predictors of first discharge and subsequent survival in patients with automatic implantable cardioverter-defibrillators. Circulation 1991; 84:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/19\">",
"      Whang W, Mittleman MA, Rich DQ, et al. Heart failure and the risk of shocks in patients with implantable cardioverter defibrillators: results from the Triggers Of Ventricular Arrhythmias (TOVA) study. Circulation 2004; 109:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/20\">",
"      Kou WH, Calkins H, Lewis RR, et al. Incidence of loss of consciousness during automatic implantable cardioverter-defibrillator shocks. Ann Intern Med 1991; 115:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/21\">",
"      Strickberger SA, Cantillon CO, Friedman PL. When should patients with lethal ventricular arrhythmia resume driving? An analysis of state regulations and physician practices. Ann Intern Med 1991; 115:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/22\">",
"      Abello M, Merino JL, Peinado R, et al. Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia. Eur Heart J 2006; 27:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/23\">",
"      Carlsson J, Schulte B, Erdogan A, et al. Prospective randomized comparison of two defibrillation safety margins in unipolar, active pectoral defibrillator therapy. Pacing Clin Electrophysiol 2003; 26:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/24\">",
"      Rosenqvist M, Beyer T, Block M, et al. Adverse events with transvenous implantable cardioverter-defibrillators: a prospective multicenter study. European 7219 Jewel ICD investigators. Circulation 1998; 98:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/25\">",
"      Grimm W, Flores BF, Marchlinski FE. Electrocardiographically documented unnecessary, spontaneous shocks in 241 patients with implantable cardioverter defibrillators. Pacing Clin Electrophysiol 1992; 15:1667.",
"     </a>",
"    </li>",
"    <li>",
"     J Am Coll Cardiol. 2007 Dec 4;50(23):2233-40.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/27\">",
"      Curtis AB, Conti JB, Tucker KJ, et al. Motor vehicle accidents in patients with an implantable cardioverter-defibrillator. J Am Coll Cardiol 1995; 26:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/28\">",
"      Conti JB, Woodard DA, Tucker KJ, et al. Modification of patient driving behavior after implantation of a cardioverter defibrillator. Pacing Clin Electrophysiol 1997; 20:2200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/29\">",
"      Akiyama T, Powell JL, Mitchell LB, et al. Resumption of driving after life-threatening ventricular tachyarrhythmia. N Engl J Med 2001; 345:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/30\">",
"      Trappe HJ, Wenzlaff P, Grellman G. Should patients with implantable cardioverter-defibrillators be allowed to drive? Observations in 291 patients from a single center over an 11-year period. J Interv Card Electrophysiol 1998; 2:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/31\">",
"      Assessment of the cardiac patient for fitness to drive. Can J Cardiol 1992; 8:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/32\">",
"      Epstein AE, Miles WM, Benditt DG, et al. Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations. A medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology. Circulation 1996; 94:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/33\">",
"      Jung W, Anderson M, Camm AJ, et al. Recommendations for driving of patients with implantable cardioverter defibrillators. Study Group on 'ICD and Driving' of the Working Groups on Cardiac Pacing and Arrhythmias of the European Society of Cardiology. Eur Heart J 1997; 18:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/34\">",
"      Epstein AE, Baessler CA, Curtis AB, et al. Addendum to \"Personal and public safety issues related to arrhythmias that may affect consciousness: implications for regulation and physician recommendations: a medical/scientific statement from the American Heart Association and the North American Society of Pacing and Electrophysiology\": public safety issues in patients with implantable defibrillators: a scientific statement from the American Heart Association and the Heart Rhythm Society. Circulation 2007; 115:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/35\">",
"      Bleakley JF, Akiyama T, Canadian Cardiovascular Society, et al. Driving and arrhythmias: implications of new data. Card Electrophysiol Rev 2003; 7:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/36\">",
"      Kim SG, Hallstrom A, Love JC, et al. Comparison of clinical characteristics and frequency of implantable defibrillator use between randomized patients in the Antiarrhythmics Vs Implantable Defibrillators (AVID) trial and nonrandomized registry patients. Am J Cardiol 1997; 80:454.",
"     </a>",
"    </li>",
"    <li>",
"     Am J Cardiol. 2005 Mar 1;95(5):665-6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?29/20/30024/abstract/38\">",
"      Maas R, Ventura R, Kretzschmar C, et al. Syncope, driving recommendations, and clinical reality: survey of patients. BMJ 2003; 326:21.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 948 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30024=[""].join("\n");
var outline_f29_20_30024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CONCERNS WITH DRIVING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms of risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Overall incidence of ventricular arrhythmias and ICD shocks",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - In patients treated for secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - In patients treated for primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Predictors of events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Risk factors for syncope",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Potential benefit of antiarrhythmic drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Significance of device charge time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Inappropriate ICD shocks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      INCIDENCE OF ICD SHOCKS WHILE DRIVING AND ACCIDENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ICD shocks while driving",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Accidents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Guidelines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Primary prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Nonsustained and hemodynamically tolerated ventricular arrhythmias without an ICD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      State laws",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Discussion with patients and family members",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H632730791\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/948\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/948|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/35/37437\" title=\"figure 1\">",
"      Frequency of arrhythmia and ICD events in AVID",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/948|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/40/30348\" title=\"table 1\">",
"      AHA NASPE driving after VT VF",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/44/35532\" title=\"table 2\">",
"      ESC driving after ICD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/48/37641?source=related_link\">",
"      Catecholaminergic polymorphic ventricular tachycardia and other polymorphic ventricular tachycardias with a normal QT interval",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24362?source=related_link\">",
"      General principles of the implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/19/5434?source=related_link\">",
"      Implantable cardioverter-defibrillators: Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/60/38850?source=related_link\">",
"      Patient information: Implantable cardioverter-defibrillators (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/24/1411?source=related_link\">",
"      Patient information: Time to stop driving? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/23/3448?source=related_link\">",
"      Pharmacologic therapy in survivors of sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f29_20_30025="IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis";
var content_f29_20_30025=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    IgG4 immunoperoxidase stain of chronic sclerosing sialadenitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chronic sclerosing sialadenitis (Kuttner tumor) with large numbers of IgG4-positive plasma cells (IgG4 immunoperoxidase stain).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Geyer J, Deshpande V. IgG4-associated sialadenitis. Curr Opinion Rheum 2011; 23:95. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30025=[""].join("\n");
var outline_f29_20_30025=null;
var title_f29_20_30026="Subcorneal pustular dermatosis on back";
var content_f29_20_30026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F52552%7EDERM%2F71995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F52552%7EDERM%2F71995&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flaccid pustules and crusted plaques are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Subcorneal pustular dermatosis close view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 576px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple flaccid pustules and areas of crusting are present on the skin. The largest lesion has a somewhat annular configuration.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30026=[""].join("\n");
var outline_f29_20_30026=null;
var title_f29_20_30027="Narrow behavior screens";
var content_f29_20_30027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected narrow-band behavioral screens",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test/age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purchasing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time frame*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Conners Rating Scale-Revised (CRS-R) (Subscales for Attention Deficit Hyperactivity Disorder)",
"         </strong>",
"        </p>",
"        <p>",
"         3 to 17 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pearson Assessments, Inc.",
"        </p>",
"        <p>",
"         Phone: 800.627.7271",
"        </p>",
"        <p>",
"         <a href=\"file://www.pearsonassessments.com\" target=\"_blank\">",
"          www.pearsonassessments.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $276 (includes manual and 25 quick score forms of various versions).",
"        </p>",
"       </td>",
"       <td>",
"        About 20 minutes",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Modified Checklist for Autism in Toddlers (M-CHAT) (1999)",
"         </strong>",
"        </p>",
"        <p>",
"         16 to 48 months",
"        </p>",
"       </td>",
"       <td>",
"        Download for free at the First Signs Web site",
"        <a href=\"file://www.firstsigns.org/downloads/m-chat.PDF\" target=\"_blank\">",
"         www.firstsigns.org/downloads/m-chat.PDF",
"        </a>",
"       </td>",
"       <td>",
"        About 5 minutes (excluding follow-up on any failed items)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not include scoring time.",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30027=[""].join("\n");
var outline_f29_20_30027=null;
var title_f29_20_30028="Ddx miliary infiltrates on CXR";
var content_f29_20_30028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F70568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F70568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of febrile illness with miliary chest x-ray infiltrates",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Infectious Diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mycobacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mycobacterium tuberculosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atypical mycobacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Fungal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endemic fungi (histoplasmosis, coccidioidomycosis, blastomycosis, paracoccidioidomycosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Bacterial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Legionella micdadei infection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Nocardiosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Staphylococcus aureus, Haemophilus influenzae and other pyogenic bacteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Psittacosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tularemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bartonellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Brucellosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Meliodosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Viral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Varicella",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cytomegalovirus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Influenza",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Measles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Parasitic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Toxoplasmosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Strongyloidiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Schistosomiasis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Neoplastic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lymphangitic spread of carcinoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mesothelioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amyloidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypersensitivity pneumonitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumoconioses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foreign-body induced vasculitis related to injection drug use",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30028=[""].join("\n");
var outline_f29_20_30028=null;
var title_f29_20_30029="Management of status epilepticus in children";
var content_f29_20_30029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F55368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F55368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Initial management of status epilepticus in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Timeline*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Supportive care",
"       </td>",
"       <td class=\"subtitle1\">",
"        Seizure therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"6\">",
"        0 to 5 minutes",
"       </td>",
"       <td>",
"        Obtain initial vital signs, including temperature",
"       </td>",
"       <td>",
"        <p>",
"         Open airway",
"        </p>",
"        <p>",
"         Suction secretions",
"        </p>",
"        <p>",
"         Administer 100 percent O2",
"        </p>",
"       </td>",
"       <td rowspan=\"6\">",
"        <p>",
"         <strong>",
"          Benzodiazepine (first line):",
"         </strong>",
"        </p>",
"        <p>",
"         Lorazepam 0.05 to 0.1 mg/kg IV or IO, maximum 4 mg",
"        </p>",
"        <p>",
"         IV or IO access not achieved within 3 minutes:",
"        </p>",
"        <p>",
"         Rectal diazepam (Diastat&reg; gel or injection solution given rectally) 0.5 mg/kg, maximum 20 mg",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Buccal midazolam 0.2 mg/kg, maximum 10 mg",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         IM midazolam 0.1-0.2 mg/kg, maximum 10 mg",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify airway obstruction and hypoxemia",
"       </td>",
"       <td>",
"        Place continuous cardiorespiratory monitors and pulse oximetry",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Identify impaired oxygenation or ventilation",
"       </td>",
"       <td>",
"        <p>",
"         Perform bag-valve-mask ventilation, as needed",
"        </p>",
"        <p>",
"         Prepare for RSI*",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain rapid bedside blood glucose and other studies, as indicated",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        Establish IV or IO access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for signs of sepsis/meningitis",
"       </td>",
"       <td>",
"        Treat hypoglycemia (IV dextrose 0.25 to 0.5 gram/kg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for signs of head trauma",
"       </td>",
"       <td>",
"        Treat fever (acetaminophen 15 mg/kg rectally)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        5 to 10 minutes",
"       </td>",
"       <td>",
"        Reevaluate vital signs, airway, breathing, and circulation",
"       </td>",
"       <td>",
"        Maintain monitoring, ventilatory support, and vascular access",
"       </td>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Benzodiazepine: second dose",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for signs of trauma, sepsis, meningitis, or encephalitis",
"       </td>",
"       <td>",
"        Give antibiotics if signs of sepsis or meningitis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        10 to 15 minutes",
"       </td>",
"       <td rowspan=\"3\">",
"        Reevaluate vital signs, airway, breathing, and circulation",
"       </td>",
"       <td>",
"        Maintain monitoring, ventilatory support, and vascular access",
"       </td>",
"       <td rowspan=\"3\">",
"        <p>",
"         <strong>",
"          Fosphenytoin (second line):",
"         </strong>",
"        </p>",
"        <p>",
"         20 mg PE per kg IV or IO",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         <strong>",
"          Phenobarbital:",
"         </strong>",
"        </p>",
"        <p>",
"         20 mg/kg IV or IO, maximum 1 gram, if toxin-induced seizure (expect respiratory depression with apnea)",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Place second IV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RSI potentially indicated*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        15 to 30 minutes",
"       </td>",
"       <td>",
"        Reevaluate vital signs, airway, breathing, and circulation",
"       </td>",
"       <td rowspan=\"2\">",
"        Maintain monitoring, ventilatory support, and vascular access",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         <strong>",
"          Phenobarbital (third line):",
"         </strong>",
"        </p>",
"        <p>",
"         20 mg/kg IV or IO, maximum 1 gram, (10 mg/kg if phenobarbital given as second line)",
"         <sup>",
"          &sect;",
"         </sup>",
"        </p>",
"        <p>",
"         OR",
"        </p>",
"        <p>",
"         Valproic acid 20 to 40 mg/kg IV or IO",
"        </p>",
"        <p>",
"         AND",
"        </p>",
"        <p>",
"         Pyridoxine 100 mg IV or IO in infants &lt;1 year of age",
"        </p>",
"        <p>",
"         Pyridoxine 70 mg/kg IV or IO, maximum 5 grams, if INH poisoning suspected",
"        </p>",
"        <p>",
"         <strong>",
"          Obtain pediatric neurology consultation (see Refractory status epilepticus algorithm)",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain continuous EEG monitoring, if available",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     IV: intravenous; IO: intraosseous; IM: intramuscular; O2: oxygen; RSI: rapid sequence endotracheal intubation; PE: phenytoin equivalents; EEG: electroencephalogram; INH: isoniazid.",
"     <br>",
"      * Rapid sequence intubation should be performed if airway, ventilation, or oxygenation cannot be maintained and if the seizure becomes prolonged.",
"      <br>",
"       <span class=\"bullet\">",
"        &bull;",
"       </span>",
"       See table \"Ancillary studies in children with status epilepticus\" (part of this document).",
"       <br>",
"        &Delta; Empiric antibiotic regimens vary depending on patient susceptibility and likely pathogen.",
"        <br>",
"         <span class=\"lozenge\">",
"          &loz;",
"         </span>",
"         Do not exceed 3 mg/kg per minute (maximum rate: 150 mg per minute). Fosphenytoin may be ineffective for toxin-induced seizures and may intensify seizures caused by cocaine and other local anesthetics, theophylline, or lindane. If fosphenytoin not available, may use phenytoin 20 mg/kg IV, do not exceed 1 mg/kg per minute (maximum rate: 50 mg per minute) with ECG monitoring.",
"         <br>",
"          &sect; Do not exceed 1 mg/kg per minute.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30029=[""].join("\n");
var outline_f29_20_30029=null;
var title_f29_20_30030="Contraindications and precautions adult vaccines";
var content_f29_20_30030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Contraindications and precautions to commonly used vaccines in adults*&bull;",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contraindications",
"       </td>",
"       <td class=\"subtitle1\">",
"        Precautions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Influenza, injectable trivalent (TIV)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         History of Guillain-Barr&eacute; syndrome (GBS) within 6 weeks of previous influenza vaccination",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Influenza, live attenuated (LAIV)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Severe allergic reaction (eg, anaphylaxis) after previous dose of any influenza vaccine or to a vaccine component, including egg protein",
"        </p>",
"        <p>",
"         Immune suppression",
"        </p>",
"        <p>",
"         Certain chronic medical conditions such as asthma, diabetes, heart or kidney disease",
"         <sup>",
"          &loz;",
"         </sup>",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         History of GBS within 6 weeks of previous influenza vaccination",
"        </p>",
"        <p>",
"         Receipt of specific antivirals (ie, amantadine, rimantadine, zanamivir, or oseltamivir) 48 hours before vaccination; avoid use of these antiviral drugs for 14 days after vaccination",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Tetanus, diphtheria, pertussis (Tdap); tetanus, diphtheria (Td)",
"       </td>",
"       <td>",
"        <p>",
"         Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"        </p>",
"        <p>",
"         For Tdap only: Encephalopathy (eg, coma, decreased level of consciousness, or prolonged seizures) not attributable to another identifiable cause within 7 days of administration of a previous dose of Tdap or diphtheria and tetanus toxoids and pertussis (DTP) or diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         GBS within 6 weeks after a previous dose of tetanus toxoid-containing vaccine",
"        </p>",
"        <p>",
"         History of arthus-type hypersensitivity reactions after a previous dose of tetanus or diphtheria toxoid-containing vaccine; defer vaccination until at least 10 years have elapsed since the last tetanus toxoid-containing vaccine",
"        </p>",
"        <p>",
"         For Tdap only: Progressive or unstable neurologic disorder, uncontrolled seizures, or progressive encephalopathy until a treatment regimen has been established and the condition has stabilized",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Varicella",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"        </p>",
"        <p>",
"         Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy",
"         <sup>",
"          &sect;",
"         </sup>",
"         or patients with human immunodeficiency virus (HIV) infection who are severely immunocompromised)",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Recent (&le;11 months) receipt of antibody-containing blood product (specific interval depends on product)",
"         <sup>",
"          &yen;",
"         </sup>",
"        </p>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         Receipt of specific antivirals (ie, acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; if possible, delay resumption of these antiviral drugs for 14 days after vaccination",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Human papillomavirus (HPV)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Zoster",
"       </td>",
"       <td>",
"        <p>",
"         Severe allergic reaction (eg, anaphylaxis) to a vaccine component",
"        </p>",
"        <p>",
"         Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, or long-term immunosuppressive therapy",
"         <sup>",
"          &sect;",
"         </sup>",
"         or patients with HIV infection who are severely immunocompromised)",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         Receipt of specific antivirals (ie, acyclovir, famciclovir, or valacyclovir) 24 hours before vaccination; if possible, avoid use of these antiviral drugs for 14 days after vaccination",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Measles, mumps, rubella (MMR)",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        <p>",
"         Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"        </p>",
"        <p>",
"         Known severe immunodeficiency (eg, from hematologic and solid tumors, receipt of chemotherapy, congenital immunodeficiency, or long-term immunosuppressive therapy",
"         <sup>",
"          &sect;",
"         </sup>",
"         or patients with HIV infection who are severely immunocompromised)",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         Recent (within 11 months) receipt of antibody-containing blood product (specific interval depends on product)",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"        <p>",
"         History of thrombocytopenia or thrombocytopenic purpura",
"        </p>",
"        <p>",
"         Need for tuberculin skin testing",
"         <sup>",
"          ������",
"         </sup>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Pneumococcal polysaccharide (PPSV)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Meningococcal, conjugate (MCV4); meningococcal, polysaccharide (MPSV4)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis A (HepA)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"       </td>",
"       <td>",
"        <p>",
"         Moderate or severe acute illness with or without fever",
"        </p>",
"        <p>",
"         Pregnancy",
"        </p>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis B (HepB)",
"       </td>",
"       <td>",
"        Severe allergic reaction (eg, anaphylaxis) after a previous dose or to a vaccine component",
"       </td>",
"       <td>",
"        Moderate or severe acute illness with or without fever",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <sup>",
"    </sup>",
"    <div class=\"footnotes\">",
"     * Vaccine package inserts and the full ACIP recommendations for these vaccines should be consulted for additional information on vaccine-related contraindications and precautions and for more information on vaccine excipients. Events or conditions listed as precautions should be reviewed carefully. Benefits of and risks for administering a specific vaccine to a person under these circumstances should be considered. If the risk from the vaccine is believed to outweigh the benefit, the vaccine should not be administered. If the benefit of vaccination is believed to outweigh the risk, the vaccine should be administered.",
"     <br>",
"      &bull; Regarding latex allergy: some types of prefilled syringes contain natural rubber latex or dry natural latex rubber. Consult the package insert for any vaccine administered.",
"      <br>",
"       &Delta;&nbsp;LAIV, MMR, and varicella vaccines can be administered on the same day. If not administered on the same day, these live vaccines should be separated by at least 28 days.",
"       <br>",
"        &loz;&nbsp;See CDC. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR 2010; 59(No. RR-8). Available at:",
"        <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm\" target=\"_blank\">",
"         file://www.cdc.gov/vaccines/pubs/acip-list.htm",
"        </a>",
"        .",
"        <br>",
"         &sect;&nbsp;Substantially immunosuppressive&nbsp;glucocorticoid dose is considered to be &ge;2 weeks of daily receipt of &ge;20 mg or &ge;2 mg/kg body weight of prednisone or equivalent.",
"         <br>",
"          &yen;&nbsp;Vaccine should be deferred for the appropriate interval if replacement immune globulin products are being administered.",
"          <br>",
"           ������&nbsp;See CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2011; 60(No. RR-2). Available at:",
"           <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm\" target=\"_blank\">",
"            file://www.cdc.gov/vaccines/pubs/acip-list.htm",
"           </a>",
"           .",
"           <br>",
"            ������&nbsp;Measles vaccination might suppress tuberculin reactivity temporarily. Measles-containing vaccine may be administered on the same day as tuberculin skin testing. If testing cannot be performed until after the day of MMR vaccination, the test should be postponed for &ge;4 weeks after the vaccination. If an urgent need exists to skin test, do so with the understanding that reactivity might be reduced by the vaccine.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Centers for Disease Control and Prevention. Contraindications and precautions to commonly used vaccines. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR Morbidity and Mortality Weekly Report 2011; 60:40.",
"       </li>",
"       <li>",
"        Atkinson W, Wolfe S, Hamborsky J (Eds). Epidemiology and prevention of vaccine preventable diseases, 12th Ed. Washington, DC: Public Health Foundation, 2011. Available at:",
"        <a href=\"file://www.cdc.gov/vaccines/pubs/pinkbook/default.htm\" target=\"_blank\">",
"         file://www.cdc.gov/vaccines/pubs/pinkbook/default.htm",
"        </a>",
"        .",
"       </li>",
"      </ol>",
"      <br>",
"       &nbsp;Adapted from: Centers for Disease Control and Prevention. Recommended Adult Immunization Schedule - United States, 2012. MMWR Morbidity and Mortality Weekly Report 2012; 61:1.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30030=[""].join("\n");
var outline_f29_20_30030=null;
var title_f29_20_30031="Distal humeral physis";
var content_f29_20_30031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F71252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F71252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal humeral physis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 223px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) At 5 months of age, the metaphysis has advanced only to the supracondylar ridges. Panel B) By 4 years of age, the edge of the metaphysis has advanced well into the area of the epicondyles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Beaty JH, Kasser JR. The elbow: Physeal fractures, apophyseal injuries of the distal humerus, avascular necrosis of the trochlea, and T-condylar fractures. In: Rockwood and Wilkins' Fractures in Children, 6th ed, Beaty JH, Kasser JR (Eds), Lippincott Williams &amp; Wilkins 2006. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f29_20_30031=[""].join("\n");
var outline_f29_20_30031=null;
